
==== Front
J Diabetes Res
J Diabetes Res
JDR
Journal of Diabetes Research
2314-6745
2314-6753
Wiley

10.1155/2024/5216113
Review Article
Radix Astragali and Its Representative Extracts for Diabetic Nephropathy: Efficacy and Molecular Mechanism
https://orcid.org/0000-0002-3442-4608
Xue Hui-zhong 1
https://orcid.org/0000-0002-7575-4427
Chen Yu 2
https://orcid.org/0000-0002-4890-1719
Wang Shi-dong 3
https://orcid.org/0000-0002-2646-0828
Yang Yi-meng 1
https://orcid.org/0000-0003-4638-361X
Cai Lu-qi 1
https://orcid.org/0000-0002-0593-2152
Zhao Jin-xi 3
https://orcid.org/0000-0002-2704-4674
Huang Wei-jun huangweijun2015@126.com
2
https://orcid.org/0000-0002-5166-315X
Xiao Yong-hua water_aqua@sina.com
3
1 The First Clinical Medical School Beijing University of Chinese Medicine, Beijing, China 100700
2 Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing Dongzhimen Hospital Beijing University of Chinese Medicine, Beijing, China 100700
3 Section II of Endocrinology & Nephropathy Department Dongzhimen Hospital Beijing University of Chinese Medicine, Beijing, China 100700
Academic Editor: Mark Yorek

2024
14 9 2024
2024 521611311 7 2023
3 5 2024
29 8 2024
Copyright © 2024 Hui-zhong Xue et al.
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Diabetic nephropathy (DN) is a common microvascular complication of diabetes mellitus (DM). Radix Astragali (RA), a frequently used Chinese herbal medicine in the Leguminosae family, Astragalus genus, with its extracts, has been proven to be effective in DN treatment both in clinical practice and experimental studies. RA and its extracts can reduce proteinuria and improve renal function. They can improve histopathology changes including thickening of the glomerular basement membrane, mesangial cell proliferation, and injury of endothelial cells, podocytes, and renal tubule cells. The mechanisms mainly benefited from antioxidative stress which involves Nrf2/ARE signaling and the PPARγ-Klotho-FoxO1 axis; antiendoplasmic reticulum stress which involves PERK-ATF4-CHOP, PERK/eIF2α, and IRE1/XBP1 pathways; regulating autophagy which involves SIRT1/NF-κB signaling and AMPK signaling; anti-inflammation which involves IL33/ST2 and NF-κB signaling; and antifibrosis which involves TGF-β1/Smads, MAPK (ERK), p38/MAPK, JNK/MAPK, Wnt/β-catenin, and PI3K/AKT/mTOR signaling pathways. This review focuses on the clinical efficacy and the pharmacological mechanism of RA and its representative extracts on DN, and we further document the traditional uses of RA and probe into the TCM theoretical basis for its application in DN.

Keywords

diabetic nephropathy
efficacy
pharmacological mechanism
Radix Astragali
traditional Chinese medicine
National Key Research and Development Program of China2018YFC1704402 Beijing Municipal Bureau of HealthState Administration of Traditional Chinese Medicine of the People's Republic of China
==== Body
pmc1. Introduction

Diabetic nephropathy (DN), also known as diabetic glomerulosclerosis, is a series of renal pathological changes resulting from diabetes mellitus (DM), including glomerular basement membrane (GBM) thickening, mesangial expansion, extracellular matrix (ECM) deposition (mainly mesangial), and tubular atrophy, leading to renal interstitial fibrosis and glomerulosclerosis [1–3]. As one of the most prevalent diabetic microvascular complications, DN has become the leading cause of end-stage kidney disease (ESRD) [3]. It is clear that mechanisms like oxidative stress, endoplasmic reticulum (ER) stress, inflammation, and autophagy impairment are involved in the pathological changes aforementioned [1]. However, the treatment of DN is still mainly limited to the control of blood glucose and blood pressure so far [4].

For DN treatment, Chinese herbal medicine (CHM) shows the modulative function of metabolism, inflammation, oxidative stress, ER stress, and fibrosis and has been proven useful in clinical practice for glycosylated hemoglobin (HbA1c), fasting blood glucose (FBG), urinary albumin excretion rate (UAER), serum creatinine (Scr), 24-h urinary protein (24 h UP), and estimated glomerular filtration rate (eGFR) [5]. Obviously, CHM is a promising therapeutic tool in DN treatment.

Radix Astragali (RA) is one of the most widely used herbs for the traditional Chinese medicine (TCM) treatment of DN, which is the dry root of Astragalus mongholicus Bunge or Astragalus membranaceus (Fisch.) Bunge [6]. It was first recorded in the book Prescriptions of Fifty-Two Diseases, written in the Warring States period (475-221 BC). Its main therapeutic effect is tonifying qi. The main pharmacological components of RA include polysaccharides, saponins, and flavonoids [7]. Among these components, astragalosides take the highest proportion of triterpene saponin content in RA [7]. As the marking compound of RA, astragaloside IV (AS-IV) has been documented with the functions of neuroprotection, liver protection, hematopoietic system protection, antivirus, antibacteria, immunity enhancement, antitumor, and antidiabetes and its complications [8, 9]. In addition, as the highest content component of RA, astragalus polysaccharide (APS) has also been widely studied, including the efficacy of immune regulation, antiaging, antitumor, reducing blood glucose and blood lipid, antifibrosis, antibacterial, antivirus, and radiation protection [10]. Flavonoid compounds in RA are mostly calycosin-7-O-β-D-glucoside, calycosin, ononin, and formononetin. Calycosin-7-O-β-D-glucoside and calycosin are the representative constituents of RA and have been proven with antitumor, neuroprotective, antidiabetic, antiosteoporosis, liver protection, and cardiovascular system protection effects [11, 12]. With the extensive efficacy of these components above, recent research has provided insight into the value of RA in the treatment of tumors, coronary heart disease, diabetes, nephritis, and so on [6, 9, 10, 12].

2. Therapeutic Effects of RA on DN

2.1. Clinical Efficacies

For DN, the therapeutic effect of RA has been proved by many clinical trials. A meta-analysis of 21 RCTs and 4 CCTs with 1804 subjects assessed the efficacy of intravenous drip of RA injection in treating Stages III–IV (Mogensen) DN. Results showed that RA injection contributed to a better effect in decreasing blood urea nitrogen (BUN), Scr, creatinine clearance rate (Ccr), and urinal protein, and increasing serum albumin (ALB) level compared with the control group (ACEi/ARB) [13]. The updated meta-analysis of 66 RCTs with 4785 patients (no restriction on the stage of renal function) including all forms of RA preparation (including tablet, granule, decoction, extract liquid, and injections) showed that adjunctive use of RA preparations on conventional therapies of ACEi/ARB could reduce albuminuria, proteinuria, and Scr in DN patients [14]. A retrospective cohort study among 6648 predialysis DN patients found RA users with lower all-cause mortality compared with other CHM users after a 5-year follow-up [15]. Here, we summarize the study design, main conclusions, and safety outcomes of the clinical research on RA in treating DN in the past 10 years (see Table 1). The preparation mostly used is RA injection (from 20 to 50 mL qd). RA tablets (2.2 g, bid), granules (from 4 to 15 g, qd or bid), and APS injection (250 mg, qd) are also common preparations and dosages. These indicate that the optimal dose for RA injections and oral preparations has not been fully validated, and whether the injection or the oral preparations can give play to higher effects still needs investigation. The frequent adverse effects (AEs) in these studies include gastrointestinal reactions, liver function damage, hyperkalemia, cough, dizziness, and headache. Parts of these AEs are common in ACEI/ARBs treatment, and no statistical difference was reported in the incidences of AEs between the treatment group and the control group. Therefore, it is not yet clear about the AEs of RA preparations. Besides, 31 out of these 50 researches did not report safety outcomes, suggesting insufficient attention to AEs of TCM. Anyhow, RA preparations exert a therapeutic effect on DN by reducing urinary protein and decreasing BUN, Scr, and Ccr. These finally result in a reduction of endpoint events, indicating the supplementary treatment value of RA for DN.

2.2. Histological Effects

When injuries occur to renal cells, the responses vary from hypertrophy, proliferation, activation, and transformation to necrosis and apoptosis. These cells can secrete a variety of cytokines and inflammatory mediators and produce varying amounts of ECM, resulting in glomerulosclerosis and tubulointerstitial fibrosis; this is how renal function is damaged [66]. If we can balance cell proliferation and apoptosis, control cell activation, and phenotypic transformation, it will greatly suppress the histopathology changes of renal tissue and increase the possibility of curing and delaying nephropathy. Therefore, it is of great significance to study the pathological effects in the treatment of disease and injury. Based on the current studies, RA has shown protective effects on specific renal intrinsic cells and emerged as a promising treatment through the modulation of multiple pathogeneses in DN progress, especially in renal fibrosis (Figure 1). Detailed effects include reducing ECM deposition; alleviating GBM and TBM thickening; ameliorating mesangial cell (MC) proliferation, hypertrophy, and contractile dysfunction; alleviating mesangial hyperplasia; inhibiting glomerular endothelial cell (GEC) apoptosis; restoring increased GEC permeability and capillary loop diameter and decreased podocyte autophagy, podocin, and nephrin expression; suppressing podocyte apoptosis, detachment, and foot process effacement; decreasing foot process width; reversing promoted epithelial-mesenchymal transition (EMT) in podocytes and renal tubular epithelial cells (TECs) (RTEC); inhibiting TECs' edema and apoptosis; and so on.

3. Mechanisms of RA and Its Representative Extracts on DN

RA and its representative extracts exhibit the renal protective effect in DN through multiple mechanisms independent of antihyperglycemic.

3.1. Inhibition of Oxidative Stress

When a free radical, independent chemical species with one or more unpaired electrons, attacks a nonradical molecule, a secondary radical molecule comes into being. The chain reaction of primary and secondary radicals leads to oxidative damage of tissues, while antioxidants can block the initial production of free radicals and the secondary production of toxic metabolites. When excessive oxidant compounds and insufficient antioxidants lead to an imbalanced redox state, this is what we call oxidative stress [67]. Hyperglycemia promotes the generation of advanced glycation end products (AGEs) in the cells, which trigger mitochondria to release excess reactive oxygen species (ROS), resulting in renal inflammation, renal cell injury, and fibrosis [5, 68].

The astragalosides in RA, mostly AS-IV, exhibit significant antioxidant effects. In diabetic db/db mice, AS-IV ameliorated podocyte injury by enhancing klotho expression and inhibiting oxidative stress through the PPARγ-Klotho-FoxO1 axis [69]. In STZ-induced hyperinsulinemia rats, AS-I could decrease the level of AGEs [70] and suppress the activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4 (Nox4) expression and the phosphorylation of ERK1/2. These actions further reduce malondialdehyde (MDA) and increase activities of antioxidant enzymes such as glutathione (GSH) peroxidase (GSH-Px), superoxide dismutase (SOD) [71, 72], and catalase (CAT) [73] and increase total antioxidative capability (T-AOC) [70], thus inhibiting oxidative stress.

In vitro results were consistent with those from animal studies. AS-IV reduced the content of ROS [73], restored Klotho expression, enhanced forkhead box transcription factor O1 (FoxO1)-dependent antioxidant activity, and upregulated Nrf2-ARE/TFAM signaling to resist oxidative stress damage, protecting HG-exposed podocytes from apoptosis [69, 72]. AS-IV also inhibited MC proliferation and glomerular contractile dysfunction caused by HG culture. These effects were achieved through the NADPH oxidase/ROS/Akt/NF-κB pathway [74, 75]. The inhibitory effect of AS-IV on oxidative stress can also protect renal tubular cells. Qi et al. [76] proved that AS-IV could attenuate glycosylated albumin (GA)-induced amplification of ROS, inhibit NADPH oxidase activity, and elevate the level of SOD units in the NRK-52E cell line. In HG-exposed HK-2 cells, AS-IV could regulate the Wnt/β-catenin pathway and Nrf2/ARE signaling pathway, an endogenous antioxidant stress pathway; further enhance the activities of SOD, GSH-Px, and CAT; and decrease the generation of MDA and ROS [77, 78]. Another study on HG-induced HK-2 cells also found that AS-IV could alleviate palmitic acid (PA)-induced cell apoptosis by decreasing ROS production and increasing P-Nrf2 levels [79]. These antioxidant processes lead to the prevention of cell apoptosis, which might be associated with the reduction of apoptotic proteins like Bax, cleaved-caspase-3, cleaved-caspase-9, and Bcl-2 [73, 77, 79].

The antioxidant effect of calycosin and calycosin-7-O-β-D-glucoside, which are also representative constituents of RA, has also been proved. In human GECs under HG stimulation, calycosin and calycosin-7-O-β-D-glucoside could attenuate AGEs-mediated cell apoptosis [80]. In NRK-52E rat renal TECs, calycosin recovered HG-induced cell viability decrease and membrane damage, reduced ROS generation and lipid peroxidation, increased the expression of (sirtuin-3) SIRT-3/SOD2 at both mRNA and protein levels, and inhibited the activity of caspase-3 [81]. In the high-fat diet(HFD)/STZ-induced T2DM rats model, calycosin treatment decreased ROS, MDA, and thioredoxin-interacting protein (TXNIP) levels, while elevated Nrf2 and TAC levels recovered mitochondrial viability and mitochondrial respiration dysfunction, indicating its potential for alleviating oxidative stress [82–84].

3.2. Inhibition of ER Stress

The main physiological function of the ER is to synthesize proteins. Pathophysiological stress conditions may interfere with normal protein folding and cause accumulation and aggregation of misfolded and unfolded proteins (UPR), inducing cellular toxicity. ER stress occurs when excess UPR accumulates beyond the load that the cell can deal with [85]. HG condition leads to altered protein glycosylation, which can interfere with protein folding, causing the accumulation of misfolded and UPR in the ER and contributing to ER stress, which could be cytotoxic after prolonged processes [85, 86].

In HFD and STZ-induced DN rats, intragastric AS-IV could alleviate RTEC apoptosis by downregulating the expression of ER stress-related proteins like p-PERK, ATF4, and CHOP and restoring the balance of Bax and Bcl-2 expression [87]. In STZ-induced DN rats, AS-IV could also alleviate ER stress-induced podocyte apoptosis by suppressing the PERK-ATF4-CHOP pathway [88]; inhibiting the expression of ORP150 and GRP78; and downregulating the phosphorylation of PERK, eIF2α, and JNK [89]. In db/db mice and podocytes under HG or PA stimulation, AS-IV ameliorated podocyte apoptosis by attenuating ER stress by restoration of SERCA2 expression and activation [90, 91]. Overall, AS-IV exerts its anti-ER stress effect by blocking the PERK-ATF4-CHOP, PERK/eIF2α, and IRE1/JNK pathways; upregulating SERCA2 expression; and downregulating ORP150 and GRP78 expression.

3.3. Control of Regulated Cell Death (RCD)

Physiologically, RCD clears unwanted cells, but in some pathological situations, disproportionate responses can contribute to the detrimental loss of kidney cells [92]. Based on molecular and essential aspects of the cell death process, the RCD process can be categorized into different modalities such as intrinsic apoptosis, extrinsic apoptosis, MPT-driven necrosis, necroptosis, ferroptosis, pyroptosis, parthanatos, entotic cell death, NETotic cell death, lysosome-dependent cell death, autophagy-dependent cell death, and immunogenic cell death.

Pyroptosis is triggered by perturbations of extracellular or intracellular homeostasis related to innate immunity manifesting with a peculiar form of chromatin condensation as well as cellular swelling culminating with plasma membrane permeabilization [93]. Pyroptosis generally relies on the activation of one or more pyroptotic caspases (caspase-1, caspase-4, caspase-5, and caspase-11) and is always associated with the activation and secretion of the two prominent proinflammatory cytokines, interleukin-1β (IL-1β) and IL-18 [94]. In the db/db mouse model, AS-IV inhibited the expression levels of NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome, apoptosis-associated speck-like protein (ASC), caspase-1, and IL-1β in the renal cortex and reduced the serum levels of TNF-α and monocyte chemoattractant protein-1 (MCP-1), thus protecting podocytes from pyroptosis accompanied by the upregulation of the podocyte markers podocin and synaptopodin [95, 96]. In STZ-induced rats, oral treatment with calycosin decreased Scr, BUN, and proteinuria levels; escalated urine Ccr; and alleviated interstitial collagen deposition and GBM thickening. These alternations were accompanied by decreased levels of serum LDH and IL-1β, renal NF-κBp65, pyroptotic-related proteins (TXNIP and NLRP3), and MDA and elevated IL-10, TAC, and Nrf2 expression, indicating that the renal-protective effect of calycosin might be associated with the modulation of oxidative stress NLRP3 and TXNIP-mediated pyroptotic signaling [84].

Ferroptosis is a form of RCD characterized by the iron-dependent accumulation of lipid hydroperoxides. It could be induced by the accumulation of glutamate, iron, or polyunsaturated fatty acid phospholipids, or by depletion of endogenous inhibitors of ferroptosis, such as reduced GSH, NADPH, Phospholipid Peroxidase Glutathione Peroxidase 4 (GPX4), or vitamin E [97]. Calycosin has been proven to be able to regulate ferroptosis in diabetic kidney disease through in vivo and in vitro studies. In db/db mice, it decreased BUN and Cr, alleviated tubular dilatation and collagen deposition, and reversed the loss of the proximal tubule brush border. In HG-treated HK-2 cells, it increased cell viability. These were achieved by the upregulation of GPX4, inhibition of lipid ROS production, and nuclear receptor coactivator 4 (NCOA4) expression, which are all correlated with ferroptosis [98].

Autophagy, a process of degrading damaged proteins and macromolecules, is a cellular protective mechanism. The autophagy levels of renal cells (including podocytes, proximal renal tubules, MCs, and endothelial cells) are downregulated in hyperglycemia conditions, which can promote the development of DN [99]. AS-IV can restore the autophagy of podocytes by inhibiting AMPKα activation, as proved by the upregulation of autophagy-related proteins LC3A/B, Beclin-1, and autophagy-related protein 12 (Atg12) and downregulation of autophagy-related protein p62 (p62) [90]. In MCs, AS-IV can also regulate Beclin-1 and LC3 II through SIRT1/NF-κB signaling, subsequently suppressing MC proliferation [100].

3.4. Anti-Inflammatory Effect

Diabetes can be regarded as chronic low-grade inflammation or a preinflammatory state. Inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, activate a variety of signal pathways, resulting in insulin resistance and decreased insulin secretion, and promote the development of diabetes [101].

Studies suggested that AS-IV could restore IL-1β, IL-4, IL-6, TNF-α, MCP-1, and ICAM-1 overproduction in STZ-induced rats, indicating its effect on ameliorating renal injury by inhibiting NF-κB-mediated inflammatory gene expression [71, 78, 102]. APS and calycosin could also ameliorate inflammation in DN kidneys by suppressing the NF-κB-dependent signaling pathway, confirmed by the downregulation of Toll-like receptor 4 (TLR4) and the phosphorylation of IκBα and NF-κB p65 and the expression of TNF-α, IL-1β, and MCP-1 in diabetic rats/mice, AGEs-treated mouse TECs, and HG-treated mouse podocytes [103–105]. Moreover, in the HFD/STZ-induced T2DM rat model, calycosin has shown the ability to modulate IL33/ST2 signaling and decrease levels of inflammatory cytokines such as NF-κB p65, TNF-α, and IL-1β [82].

3.5. Inhibition of Renal Fibrosis

Renal fibrosis is characterized by tubule atrophy, interstitial chronic inflammation and fibrogenesis, glomerulosclerosis, and vascular rarefaction [106]. Abnormal activation of several cell growth factors such as transforming growth factor beta (TGF-β), connective tissue growth factor (CTGF), angiotensin II (Ang II), hepatocyte growth factor (HGF), and their receptors are the mediators of renal fibrosis [107, 108].

In the human glomerulus, known cell types include GECs, podocytes, MCs, and parietal epithelial cells. Podocyte injury results in their detachment and loss, which is one of the major determinants of glomerular injury and glomerulosclerosis. The manner in which endothelial cells contribute to glomerulosclerosis is to regenerate and produce GBM, causing the thickening of GBM. Similarly, the pathological changes of MCs and parietal epithelial cells during fibrosis progress are to regenerate, proliferate, and produce ECM, which also potentially leads to glomerulosclerosis [106, 109].

As for the renal tubule, in the DN process, infiltrating immune cells, glucosuria, and albuminuria can trigger the secretion of proinflammatory and profibrotic mediators in proximal TECs, resulting in interstitial inflammation and fibrosis [110]. EMT is one of the pathognomonic pathological processes of interstitial fibrosis, which manifests as the loss of the original phenotype of TECs, the destruction of the renal tubular basement membrane, the shift of TECs from the renal tubules to the interstitium through the damaged basement membrane, and the transformation of TECs into myofibroblasts expressing α-smooth muscle actin (α-SMA) [108]. Another typical pathological change of interstitial fibrosis is ECM accumulation, which represents the excess accumulation of matrix proteins including Types Ι, III, V, VI, VII, and XV collagen, as well as the adhesive glycoprotein fibronectin (FN), which results in the expansion of the space between the tubular basement membrane and peritubular capillaries [111].

Vitro experiments on HK-2 and NRK-52E cell lines have confirmed that AS-IV can reverse the HG or GA-induced increase in the expression of α-SMA and decrease the expression of E-cadherin to attenuate EMT [76, 112]. In MCs under HG condition, both AS-IV and astragalosides could inhibit increased cell proliferation; downregulate the expression of CTGF, TGF-β1, and fibrosis-related mRNAs including miR-192 and miR-21; alleviate the increased levels of β-catenin and Smad3; decrease the level of Smad7 regulated by miR-21 overproduction; and reduce major ECM proteins including Type IV collagen (Col-IV) and FN [113–115]. In HG-exposed TECs, AS-IV could also decrease the production of β-catenin, TGF-β1, α-SMA, Col-IV, and FN and increase E-cadherin expression, antagonizing EMT and renal fibrosis [78, 116, 117]. In mouse renal fibroblasts cultured with TGF-β1, AS-IV treatment suppressed the cell viability and the overexpression of α-SMA, Col-IV, and FN, further inhibiting fibroblast differentiation and ECM formation [118]. These effects were reached probably through Wnt/β-catenin, TGF-β1/Smads, mTORC1/p70S6K, MAPK, NF-κB, and RAF/MEK/ERK pathways [78, 112–118].

AS-IV and AS-I also exhibited antifibrosis effects on STZ-induced DN rats, as proved by the amelioration of glomerular mesangial hyperplasia and GBM thickening [70, 114]. Mechanisms include the inhibition of the expression of TGF-β1 and its downstream mediator Smad3, increase of the expression of Smad7 (which can negatively regulate Smad3), and downregulation of miR-192, α-SMA, and Type 1 collagen (Col-1) expression via the TGF-β1/Smad/miR-192 signaling pathway [114]. Studies of AS-IV and astragaloside on diabetic KKAy mice decreased α-SMA, Col-IV, and FN expression and showed suppression effect of glomerulosclerosis and renal interstitial fibrosis accompanied by the downregulation of miR-21, TGF-β1, Smad2/3, and β-catenin [115, 119]. These results also proved that the TGF-β/Smads and Wnt/β-catenin pathways were involved in the antifibrosis effect of RA. In diabetic mouse models, AS-IV also exhibited its effect of ameliorating mesangial expansion, reducing ECM deposition through inhibition of CX3CL1-RAF/MEK/ERK, MEK1/2ERK1/2-RSK2, Akt/mTOR, NF-κB, and Erk1/2 signaling pathways [112, 120, 121].

Additionally, in vitro and in vivo studies demonstrated that calycosin treatment could inhibit renal ECM deposition and modulate fibrotic processes [80, 82].

3.6. Other Mechanisms Against DN

Hyperglycemia-induced GEC injury manifests as cell dysfunction, even apoptosis. Endothelial dysfunction in diabetes is associated with impaired abilities of nitric oxide (NO) production and eNOS activation [122]. AS-IV has been proven to be able to promote the synthesis of NO, enhancing eNOS phosphorylation and activity, thereby reversing HG-treated human renal GEC permeability and apoptosis [123].

The pathological changes of podocytes in DN include hypertrophy, dedifferentiation (EMT), impaired autophagy, podocyte detachment, effacement, and apoptosis [68]. α3β1 integrin acts as an anchor to connect the podocyte with the GBM. AS-IV can increase the expression of α3β1 integrin and decrease the expression of integrin-linked kinase (ILK), subsequently ameliorate podocyte adhesion dysfunction, inhibit podocyte detachment [124], and increase podocyte density [125]. TRPC6, one of the Ca2+ ion channels expressed in podocytes, is involved in NFAT-dependent cell apoptosis. AS-IV can prevent HG-exposed podocyte apoptosis via downregulation of TRPC6, NFAT2, and Bax expression [126]. Apoptosis of podocytes is also associated with TRAF5-mediated NF-κB activation [127]. AS-IV increases the expression of miR-378 and elevates the TUG1 level, both of which can attenuate the TRAF5 level, thus suppressing podocyte apoptosis in DN rats and HG-treated MPC5 cells [128, 129].

Adiponectin is an adipose-derived hormone. It has proven to be beneficial in DN by means of a comprehensive effect of antioxidation, anti-inflammatory, modulating RCD, anti-ER stress, antifibrosis, and improving endothelial dysfunction. However, during the progress of glucose and lipid metabolism disorders, the secretion of adiponectin is downregulated [130–132]. In a db/db mouse model, HG-treated human GECs, and murine podocytes, AdipoRon, a synthetic adiponectin receptor agonist, showed the ability to activate intrarenal AdipoR1 and AdipoR2, followed by activating the CaMKKb/phosphorylated Ser431LKB1/phosphorylated Thr172AMPK/PPARα pathway, thus decreasing oxidative stress and apoptosis and improving endothelial dysfunction [133]. Two other compounds derived from RA (astragaloside II and isoastragaloside I) can activate AMPK via the increase of adiponectin secretion in db/db mice [134]. Therefore, increasing the secretion of adiponectin may be an important way for RA to treat DN.

Another study on db/db mice demonstrated that AS-IV reduced glomerular mesangial matrix, proximal tubular area, and urinary NAG (a marker of proximal tubular injury) excretion by modulating the mitochondrial quality control network, as evidenced by the downregulation of the levels of mitochondrial fission-associated protein including Drp-1, Fis-1, and MFF and mitophagy-associated protein including PTEN-induced putative kinase 1 (PINK1), Parkin, p-Parkin (Ser 65), and LC-3II [135].

The pharmacological effects and targets of RA and its representative extracts on DN are summarized in Table 2 and Figure 2.

4. Traditional Views and the Link With Pharmacological Properties of RA

In TCM theory, qi is the source of energy, constituting the human body and sustaining its life activity, exerting a positive regulatory effect on various life activities. The qi-tonifying efficacy of RA has long been recognized, since the Shennong Materia Medica Sutra, which was completed in the Eastern Han Dynasty (25-220 AD), has described RA as “tonifying deficiency, curing illness of children, treating exogenous diseases, and cutaneous infection.” In later generations, based on the qi-tonifying efficacy, the indication of RA extended to various syndromes involving the pathogenesis of qi-deficiency, including strengthening the body, consolidating the defensive function of the body (for treating fatigue, spontaneous sweating, loss of appetite, etc.), facilitating dispelling pathogenic qi (for treating exogenous diseases and cutaneous infection), propelling blood (for treating numbness and pain in limbs) and body fluid (for treating edema), and preventing the leakage of essences (for treating diarrhea, polyuria, proteinuria, and hematuria). Based on these traditional uses, RA has been much more in-depth applied. Its anti-inflammatory, antioxidation, anticancer, immunomodulation, and antiviral mechanisms can be related to the positive regulation of qi on the human body, thereby exerting the effects of antiaging, antidiabetes, heart protection, renal protection, liver protection, and neuroprotection [7, 136, 137].

TCM regards heat impairing qi and yin as the basic pathogenesis of DM, and the qi-deficiency is persistent in the course of DN from the beginning to the end stage. With the development of DN, qi-deficiency gradually becomes more severe, damaging other physiological functions, such as propelling body fluid, preventing the leakage of urine protein, and excreting toxins. Modern studies support that qi-deficiency syndrome is closely related to immune dysfunction, oxidative stress, inflammation, abnormalities in energy metabolism, and so on [138]. In the qi-deficiency animal models, the contents of eNOS and NO and SOD activity decreased, and the content of MDA and inflammatory factors like IL-1β, IFN-γ, IL-6, IL-8, and TNF-α increased [138]. These findings coincide with the changes in the progression of DN.

The components of another typical CHM with the primary efficacy of qi-tonifying, Panax ginseng C.A. Mey. (Renshen), have been proven to show similar pharmacological properties to the RA extracts, such as regulating oxidative stress, inflammation, autophagy, and apoptosis [139] and increasing NO synthesis [140]. Some TCM prescriptions or herbal pairs with qi-tonifying as the core function also suggest the potential mechanism of the qi-tonifying effect. Powder for restoring pulse beating (Shengmai Powder), decoction of four mild drugs (Sijunzi Decoction), and other TCM prescriptions for qi-tonifying, as well as commonly used herbal pairs such as ginseng and RA, have been proven to be able to regulate Akt signaling in diabetic-related cognitive decline models and reverse memory deficits in diabetic rats [141]. In the ischemic heart disease model, these prescriptions or herbal pairs can regulate AMPK, IL-6 [142], and TNF signaling [143] and upregulate Nrf2 expression, inhibiting JNK phosphorylation and cardiomyocyte apoptosis [144]. In Alzheimer's disease, they can regulate IL-1β and glycogen synthase kinase-3β (GSK-3β) signaling and mitigate the oxidative damage of nerve cells [145]. In chronic kidney disease (CKD), they can enhance mitochondrial energy generation and antioxidant status; eliminate free radicals; protect renal cells; improve renal microcirculation; and reduce Scr, BUN, and urinary protein [146]. Based on the above findings, the mechanisms and effects of qi-tonifying can correspond to the mechanisms and effects of RA and its extracts for treating DN.

By virtue of its superior qi-tonifying efficacy, RA positively affects DN from the perspective of both TCM and modern medicine. The effectiveness of medication based on TCM theory has been recognized by clinical and laboratory research, which confirms TCM theory. Therefore, treating DN with the qi-tonifying method deserves more clinical practice and further corroboration.

5. AEs and Toxicity of RA

The AEs and toxicity of RA have been studied. In most in vitro studies, the concentrations of AS-IV were under 100 μmol/L, and no evidence of cytotoxicity was shown, while AS-IV 200 μmol/L could decrease cell viability [77, 79]. When treated with calycosin at doses above 10 μmol/L, a decrease in cell viability was observed [105]. As for in vivo experiments, feeding experiments using APS and total flavonoids showed no obvious AEs, and toxicity tests of RA total glucoside, APS, and astragalus saponins revealed that the safety dosage ranges of these components are more than 35 times the dose of humans [136].

Some clinical trials also reported some AEs of RA. In a meta-analysis of clinical studies using RA preparations to treat DN, 20 out of 66 studies reported safety outcomes [14]. Among the 376 participants in the five studies that reported AEs, there were 18 cases of dry cough (16 cases were treated with benazepril, and symptoms relieved without treatment within 2 weeks), 15 cases of Scr elevated more than 30% from baseline (Scr went down with treatment later in 13 cases), 13 cases of dizziness, three cases of angioedema, and a case of hyperkalemia. Since all the studies took ACEi/ARB as the initial therapy, which may lead to all the AEs aforementioned, and no statistical difference in the incidences of each AE was found between the treatment group and control group, the AEs of RA itself seem insignificant. However, in consideration of the data of these five studies, the facticity of the safety outcomes of the other 15 studies which reported no AEs needs to be questioned. According to the results summarized in Table 1, the AEs of RA preparations have received more attention in recent years. These outcomes indicate that serious AEs have not been found in the treatment of DN with RA preparations and, at the same time, throw light on inadequate attention to the safety evaluation of RA preparations in clinical studies. In addition, there is currently insufficient clinical evidence to evaluate the risks and benefits of the use of RA preparations in patients with ESRD. More convincing evidence is still needed.

6. Discussion and Prospect

The current treatment strategy for DN is still insufficient. In addition to glycemic control, a few drugs, like SGLT2 inhibitors, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), ACEI/ARBs, and finerenone, have been proven to be protective of renal function [147], while side effects are not rare in the application of these drugs, for example, risk of genital infection and diabetic ketoacidosis (DKA) for SGLT2 inhibitors [148]; gastrointestinal events and risk of thyroid C-cell tumors and injection site reactions for GLP-1 RAs [149]; cough, functional renal insufficiency, hyperkalemia, angioedema, and so on for ACEI/ARBs [150]; and hyperkalemia for finerenone [4, 151]. Much less, renal insufficiency itself is the reason that restricts the use of many drugs. Despite the fact that all these approaches can only slow down but not halt the progression of DN, herbal medicines with composite compounds exhibit efficacy in a multitarget, multipathway manner compared with these chemicals and should be given full focus.

Among the aforementioned extracts, the pharmacological effects of AS-IV are achieved through the mechanisms of antioxidant, anti-inflammatory, anti-ER stress, antiapoptosis, antipyroptosis, antifibrosis, and immune regulation, improving endothelial dysfunction, promoting peripheral nerve regeneration, and limiting lipid deposition [8]. APS shows the abilities of immune regulation, anti-inflammation, antioxidant, and anti-ER stress, promoting endothelial cell proliferation, inhibiting liver glycosylation, inhibiting islet β cell apoptosis, and increasing insulin sensitivity in peripheral tissues [10, 152]. Calycosin exhibits effects of anti-inflammatory, antioxidant, antipyroptosis, and antiferroptosis, promoting osteogenesis, endothelial cell proliferation, and vascular dilation [11, 12]. The pharmacological mechanisms of these components, which are widely studied, partially overlap, including anti-inflammatory and antioxidation and improving vascular endothelial function. In addition, AS-IV and calycosin have been proven to be able to antipyroptosis and antifibrosis. AS-IV and APS can both exert anti-ER stress, antiapoptosis, antibacterial, antiviral, and immune-regulation effects. The differences among the pharmacological effects of each component may provide new perspectives for drug development for different diseases or pathological processes. Among its representative components, AS-IV, as the constituent for quality evaluation in the Chinese Pharmacopeia, gains the most interest from researchers in the DN field, while APS, calycosin-7-O-β-D-glucoside, calycosin, and other components are relatively less investigated. Based on its comprehensive effects of antioxidation, anti-inflammatory, modulating regulated cell death, anti-ER stress, antifibrosis, and improving endothelial dysfunction, AS-IV could be priorly considered to be developed in the treatment of DN. However, the therapeutic effects for other diseases of APS calycosin-7-O-β-D-glucoside and calycosin also suggest their potential pharmacological mechanisms on DN, and more evidence remains to be explored to provide new strategies for the treatment of DN in the future.

Except for these representative components, network pharmacology studies have found many other flavonoids in RA with multitudinous targets against DN, including quercetin, formononetin, kaempferol, 7-Omethylisomucronulatol, and isorhamnetin [153]. Kaempferol acts its renal protective effects through the anti-inflammation, antioxidation, and antifibrosis mechanisms [154–157]. The pharmacological effects of quercetin are similar to kaempferol, which acts on endothelium, TECs, MCs, and podocytes to alleviate DN [158–162]. These protective effects are reflected in improvements in the renal index, urine protein, uric acid, urine ALB, and Scr levels [163]. Formononetin can also alleviate oxidative stress, restore mitochondrion function, and inhibit renal fibrosis in DN models [164–167]. Isorhamnetin, as an anti-inflammatory and antioxidation agent, shows a definite antidiabetic effect and the ability to modulate autophagy in renal tissues [168, 169]. These components share common pharmacological mechanisms with the representative components of RA. Together, the multiple components of RA act in coordination with each other and contribute to the treatment of DN.

7. Conclusion

Based on the present findings, RA and its extracts have a multiscale act on various mechanisms of DN as well as in histopathological changes in most parts of the nephron. Besides, these components show definite protection effects on renal function. Specific mechanisms include inhibition of oxidative stress, inhibition of ER stress, modulation of regulated cell death, anti-inflammation, and inhibition of renal fibrosis. Although many studies have elucidated the therapeutic effect of RA on DN through histopathological changes, clinically, biopsy is not the prior choice of DN patients. The clinical efficacy evaluation still relies on the detection of biochemical indexes. The histopathological examination reflects structure, while biochemical index detection focuses on function, which is what truly matters for patients. The scarcity and low quality of clinical trials failed to provide sufficient evidence to prove how much RA can improve renal function and how safe the different types of RA preparations are, which hiders the usage of RA in clinical practice. It is worth noting that researchers have developed mediums that can encapsulate active extracts of herbal medicine including RA, enhancing the solubility and sustained release, making it possible to promote stable and highly bioavailability herbal ingredient preparations to clinical practice [83, 170, 171]. Further, strictly designed large-scale, long-term follow-up trials are warranted to provide definitive evidence for the clinical efficacy of RA and its extracts. Still, these findings pave the way for the future development of RA and its extracts as potential therapeutic preparations in the management of DN.

Acknowledgments

The artwork was produced by OmniGraffle (Version 7.21.2, the Omni Group, Seattle, WA, United States). This work was supported by the National Excellent Clinical Talents Training Program for Traditional Chinese Medicine of the State Administration of TCM, the Capital Health Development Research Special Project of the Beijing Municipal Health Commission, and the National Key R&D Program of China (2018YFC1704402).

Nomenclature

24 h UP 24-h urinary protein

α-SMA α-smooth muscle actin

β2-MG β2-microglobulin

AEs adverse effects

AGEs advanced glycation end products

AIF apoptosis-inducing factor

Akt protein kinase B

ALB albumin

AMPK adenosine 5′-monophosphate (AMP)-activated protein kinase

Ang II angiotensin II

APAF-1 apoptotic protease activating factor-1

APC adenomatous polyposis coli

APSs astragalus polysaccharides

ASC apoptosis-associated speck-like protein

AS-IV astragaloside IV

ASK1 apoptosis signal-regulating kinase 1

ATF4/6 activating transcription factor 4/6

Atg12 autophagy-related protein 12

Axin axis inhibition protein

Bax Bcl2-associated X protein

Bcl-2 B-cell lymphoma-2

BUN blood urea nitrogen

CaMKKb calcium/calmodulin-dependent protein kinase kinase

Caspase-3/9/12 cysteinyl aspartate specific proteinase-3/9/12

CAT catalase

Ccr creatinine clearance rate

CHM Chinese herbal medicine

CHOP C/EBP-homologous protein

CKD chronic kidney disease

Col-1 Type 1 collagen

Col-IV Type IV collagen

CRP C-reactive protein

CTGF connective tissue growth factor

CX3CL1 chemokine C-X3-C-motif ligand 1

Cys-C serum cystatin C

Cyt C cytochrome C

DKA diabetic ketoacidosis

DKD diabetic kidney disease

DM diabetes mellitus

DN diabetic nephropathy

ECM extracellular matrix

eGFR estimated glomerular filtration rate

eIF2α eukaryotic initiation factor 2α

EMT epithelial-mesenchymal transition

eNOS endothelial nitric oxide synthase

ER stress endoplasmic reticulum stress

ERK1/2 extracellular signal-regulated kinase 1/2

ESRD end-stage kidney disease

FBG fasting blood glucose

FN fibronectin

FoxO1 forkhead box transcription factor O1

GA glycosylated albumin

GBM glomerular basement membrane

GECs glomerular endothelial cells

GLP-1 RAs glucagon-like peptide 1 receptor agonists

GPX4 phospholipid peroxidase glutathione peroxidase 4

GRP78 glucose-regulated protein 78 kD

GSH glutathione

GSH-Px glutathione peroxidase

GSK-3β glycogen synthase kinase-3β

HbA1c glycosylated hemoglobin

HFD high-fat diet

HGF hepatocyte growth factor

IFN-γ interferon-γ

ILK integrin-linked kinase

iNOS inducible nitric oxide synthase

IRE1 inositol requiring enzyme 1

IκBα inhibitor of NF-κB

JNK c-Jun N-terminal kinase

LC3 microtubule-associated protein 1 light chain 3

lncRNA-TUG1 long noncoding RNA taurine upregulated 1

mALB microalbumin

MAPK mitogen-activated protein kinase

MCP-1 monocyte chemoattractant protein-1

MCs mesangial cells

MDA malondialdehyde

MEK1/2 mitogen-activated protein kinase kinase 1/2

miR-21/192/378 microRNA 21/192/378

MPC5 cells murine podocyte cell line

mTORC1 mammalian target of rapamycin complex 1

NADPH nicotinamide adenine dinucleotide phosphate

NAG N-acetyl-β-D aminoglucosidase

NCOA4 nuclear receptor coactivator 4

NFAT2 nuclear factor of activated T cells 2

NF-κB nuclear factor-κB

NLRP3 NOD-like receptor thermal protein domain associated protein 3

NO nitric oxide

NOX4 NADPH oxidase 4

Nrf2 NF-E2-related factor 2

p62 autophagy-related protein p62

P70S6k P70 ribosomal protein S6 kinase

PA palmitic acid

PERK protein kinase R (PKR)-like endoplasmic reticulum kinase

PI3K phosphatidylinositol 3-kinase

PINK1 PTEN-induced putative kinase 1

PKCα protein kinase Cα

PPARα/γ peroxisome proliferators-activated receptor α/γ

RAF Raf protein kinase

RCD regulated cell death

ROS reactive oxygen species

RSK2 ribosomal protein S6 kinase 90 kDa polypeptide 3

Scr serum creatinine

SERCA2 sarco/endoplasmic reticulum Ca2+-ATPase 2

SIRT1/3 sirtuin1/3

Smad2/3/7 drosophila mothers against decapentaplegic protein2/3/7

SOD superoxide dismutase

T-AOC total antioxidative capability

TCM traditional Chinese medicine

TECs tubular epithelial cells

TFAM mitochondrial transcription factor A

TGF-β transforming growth factor-β

TLR4 Toll-like receptor 4

TNF-α tumor necrosis factor-α

TRAF2/5 TNF receptor-associated factor 2/5

TRB3 tribbles homologous protein 3

TRPC6 transient receptor potential channel-6

TXB2 thromboxane B2

TXNIP thioredoxin-interacting protein

UACR urinary albumin to creatinine ratio

UAER urinary albumin excretion rate

UPR unfolded protein response

XBP1 X-box binding protein 1

Data Availability Statement

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Author Contributions

Hui-zhong Xue and Yu Chen have contributed equally to this work and share the first authorship. All of the authors developed the concept for the study. Hui-zhong Xue conducted the literature search and drafted the manuscript. Yong-hua Xiao and Wei-jun Huang reviewed the manuscript and made corrections. Yu Chen, Shi-dong Wang, and Jin-xi Zhao provided suggestions. Yi-meng Yang and Lu-qi Cai offered help with the literature study.

Funding

This work was supported by the National Excellent Clinical Talents Training Program for Traditional Chinese Medicine of the State Administration of TCM, the Capital Health Development Research Special Project of the Beijing Municipal Health Commission, and the National Key R&D Program of China (2018YFC1704402).

Figure 1 Main pathological effects of RA against DN. The renal protective effect of RA targets multiple parts of the nephron, including the glomerular basement membrane, mesangium (both mesangial cells and mesangial matrix), endothelium, podocytes, and tubule. Note: Symbols “↑” and “↓” represent increase and decrease, respectively.

Figure 2 Main molecular mechanisms of RA against DN. RA and its extracts demonstrate the renal protective effect in DN through the inhibition of fibrosis, oxidative stress, endoplasmic reticulum stress, inflammation, cell apoptosis, endothelial dysfunction, and promotion of autophagy, podocyte adhesion, and so on. These actions are achieved by the regulation of Bcl-2 and caspase families and signaling pathways including TGF-β1/Smads, Nrf2/ARE, MAPK/ERK, p38/MAPK, JNK/MAPK, Wnt/β-catenin, PI3K/AKT/mTOR, AMPK, NF-κB, PERK-ATF4-CHOP, IREα/XBP1, and PPARγ-Klotho-FoxO1.

Table 1 Study characteristics of the recent clinical researches of RA in treating DN.

Ref.	Baseline renal function or DN stage	Participants (T/C)	Average age (T/C)	Average history of DM (T/C)	RA preparations, dose, and frequency	Basic therapeutics, dose, and frequency	Treatment duration	Treatment effects of RA	Incidence of adverse effects (T/C)	Adverse effects of treatment group	
Chen et al. [16]	Mogensen IV	32/32	54.18/53.76	9.06/9.16	Tablet, 2.2 g, bid	Irbesartan 150 mg, qd; hydroxychloroquine 200 mg, bid	12 weeks	Scr, BUN, eGFR, 24 h UP ↓	18.75%/12.5%	4 cases of gastrointestinal reactions and 2 cases of liver function damage	
Zhang et al. [17]	Mogensen III	50/50	40.7/40.9	7.5/7.3	APS injection 250 mg, qd	Conventional therapy	2 weeks	Scr, BUN ↓	NS	NS	
Wang, Liu, and Guo [18]	Microalbuminuria, UACR ≤300 mg/g	32/30	59.5/58.1	10.26/9.25	Granules, 4.5 g, qd	Conventional therapy	3 weeks	UACR ↓	NS	NS	
Liu [19]	NS	25/25	74.63/73.86	12.11/12.21	Decoction with RA 30 g, qd	Conventional therapy	1 month	mALB, UAER, Scr ↓	NS	NS	
Zhou et al. [20]	Mogensen III–IV	40/40	58.12/57.88	6.17/6.88	APS injection 250 mg, qd	Conventional therapy	1 week	UAER, 24 h UP, Scr, BUN ↓	No AEs	No AEs	
Sheng and Chen [21]	Mogensen III	40/40	48.14/46.78	7.63/8.16	Tablet, 2.2 g, bid	Irbesartan 150 mg, qd	12 weeks	UAER ↓	12.5%/7.5%	2 cases of hyperkalemia, 2 cases of gastrointestinal reactions, and 1 case of rash	
Han [22]	NS	35/35	53.13/53.51	12.23/12.02	Injection, 20 mL, qd	Conventional therapy	4 weeks	Scr, BUN ↓	2.9%/2.9%	1 case of nausea	
Xu [23]	UAER>300 mg/24 h	50/50	57.8/58.1	9.4/9.2	Injection, 30 mL, qd	Benazepril 10 mg, qd	8 weeks	Scr, BUN, 24 h UP, mALB ↓	10%/14%	2 cases of dizziness, 2 cases of cough, and 1 case of headache	
Sun [24]	NS	42/42	57.40/57.62	9.28/8.76	Injection, 40 mL, qd	Calcium dobesilate 0.5 g, tid	2 weeks	Scr, BUN, UAER ↓	NS	NS	
Chen et al. [25]	Mogensen III	42/43	61.3/61.8	NS	Granules, 4 g, bid	Losartan 100 mg, qd	12 weeks	24 h UP, UACR ↓	NS	NS	
Xu and Liu [26]	Mogensen III	43/43	58.4/59.2	9.8/10.2	Injection, 30 mL, qd	Alprostadil injection 20 μg, qd	4 weeks	Scr, BUN, UAER, urine β2-MG ↓	2.3%/18.6%	1 case of allergy	
Wang and Du [27]	NS	26/26	39.4/56.5	3.5/3.6	Granules, 15 g, bid	Valsartan 80 mg, qd	3 weeks	Scr, 24 h UP, mALB ↓	NS	NS	
Wang and Zhang [28]	Mogensen III	35/35	54.47/51.65	7.06/6.78	Injection, 50 mL, qd	Atorvastatin 20 mg, qd	3 months	SCr, UAER, TGF-β1 ↓, eGFR ↑	No AEs	No AEs	
Wang [29]	Mogensen III	48/48	51.8/52.4	6.2/6.5	Injection, 40 mL, qd	Spironolactone 20 mg, bid	1 month	mALB, BUN, Scr, UAER, β2-MG ↓	4.2%/6.3%	1 case of dizziness and 1 case of cough	
Sun [30]	Mogensen III	50/50	59.61/59.48	5.58/5.79	Injection, 20 mL, qd	Valsartan 80 mg, qd	2 weeks	Scr, BUN, 24 h UP ↓	No AEs	No AEs	
Qiao [31]	NS	40/40	58.5/58.5	7.5/6.5	Injection, 20 mL, qd	Benazepril 10 mg, qd	4 weeks	Scr, 24 h UP, mALB ↓	NS	NS	
Liu and Chen [32]	Mogensen III	60/60	55.8/55.3	12.3/12.2	Injection, 30 mL, qd	Conventional therapy	3 weeks	Cys-C, mALB, UACR, β2-MG, NAG ↓	No AEs	No AEs	
Zhou and Zhang [33]	Mogensen III–IV	50/50	50.3/50.2	10.2/11.1	Injection, 40 mL, qd	Conventional therapy	10~15 days	24 h UP, Scr ↓, serum ALB ↑	NS	NS	
Zhang [34]	Mogensen III	89/89	54.8/55.1	4.9/5.1	Injection, 20 mL, qd	Valsartan 80 mg, qd	3 weeks	Scr, BUN, urine β2-MG, mALB ↓, serum ALB ↑	NS	NS	
Wang [35]	NS	20/20	64.13/64.25	1.39/1.24	Granules, 4 g, bid	Valsartan 80 mg, qd	3 months	24 h UP, Scr ↓	NS	NS	
Qi [36]	NS	70/68	39/40	NS	Injection, 30 mL, qd	Captopril 12.5 mg, bid	4 weeks	24 h UP ↓, serum ALB ↑	NS	NS	
Li and Xu [37]	Mogensen III	55/55	NS(48~73)	7.8/7.9	Injection, 50 mL, qd	Irbesartan 150 mg, qd	1 month	Scr, BUN, UAER, 24 h UP ↓	NS	NS	
Li [38]	NS	43/43	54.7/54.0	7.3/7.5	Injection, 20 mL, qd	Benazepril 5 mg, qd	4 weeks	Scr, BUN, UAER ↓	4.7%/7.0%	1 case of dizziness and 1 case of cough	
He et al. [39]	UAER>30 mg/24 h, Scr ≤350 μmol/L	18/18	51/50	NS	Injection, 20 mL, qd	Captopril 12.5~100 mg/day, frequency not specific	12 weeks	24 h UP ↓	No AEs	No AEs	
Y. Zhang and H. Zhang [40]	NS	30/30	47.6/46.9	NS	Injection, 40 mL, qd	ACEi, details not specific	4 weeks	UAER ↓	No AEs	No AEs	
Xiang [41]	Mogensen III	34/33	57.52/58.42	NS	Granules, 4 g, bid	Valsartan 80 mg, qd	3 months	mALB, 24 h UP, UAER, Cys-C, β2-MG, NAG ↓	No AEs	No AEs	
Tang [42]	Mogensen III	72/72	52.48/52.13	NS	Injection, 20 mL, qd	Valsartan 80 mg, qd	4 weeks	Scr, BUN, 24 h UP, β2-MG ↓	NS	NS	
Ren [43]	Mogensen III	45/45	57.6/56.9	6.7/6.6	Injection, 50 mL, qd	Irbesartan 150 mg, qd	1 month	Scr, Ccr, 24 h UP, UAER, β2-MG ↓	NS	NS	
Liu and Deng [44]	NS	37/37	60.2/56.7	9.8/10.6	Injection, 20 mL, qd	Valsartan 80 mg, qd	3 weeks	Scr, 24 h UP, mALB ↓	NS	NS	
Li [45]	UAER>30 mg/24 h	23/23	56.9/56.2	6.7/6.2	Injection, 40 mL, qd	Enalapril 10 mg, qd	2 weeks	Scr, BUN, 24 h UP, UAER ↓	13%/17.4%	2 cases of cough and 1 case of headache	
Fang et al. [46]	24 h UP>3.5 g, serum ALB<30 g/L, Scr<354 μmol/L	40/40	61.9	12.1	Injection, 30 mL, qd	Alprostadil injection 10 μg, qd	2 weeks	Scr ↓, serum ALB ↑, UAER ↓	NS	NS	
Cai and Cui [47]	Mogensen III	40/40	56.5/57.2	7.8/7.9	Injection, 50 mL, qd	Benazepril 10 mg, qd	4 weeks	mALB, 24 h UP, UAER, β2-MG ↓	NS	NS	
Xiao and Liu [48]	Mogensen III	45/45	47.5/48.3	10.6/11.7	injection, 30 mL, qd	Alprostadil injection 20 μg, qd	4 weeks	Scr, BUN, UAER, urine β2-MG ↓	2.2%/0	1 case of allergy	
Wang [49]	NS	54/54	68.1/68.5	7.4/7.2	Injection, 50 mL, qd	Irbesartan 150 mg, qd	1 month	Scr, BUN, 24 h UP, UAER ↑	NS	NS	
Shi and Lin [50]	24 h UP 0.3~1 g	42/42	42.98	1.85	Injection, 40 mL, qd	Valsartan 80 mg, qd	1 week	Scr, BUN, mALB ↓	NS	NS	
Ouyang [51]	Mogensen IV	64/64	53.4/52.8	6.8/7.0	Injection, 30 mL, qd	Atorvastatin 20 mg, qd	4 weeks	Scr, 24 h UP, CRP ↓	NS	NS	
Luo [52]	NS	50/50	58.6/59.1	11.3/11.5	Injection, 20 mL, qd	Valsartan 80 mg, qd or bid	2 weeks	Scr, BUN, β2-MG ↓	No AEs	No AEs	
Liu, Meng, and Wei [53]	Mogensen III	36/36	54.0/53.8	6.4/6.3	Injection, 50 mL, qd	Benazepril 10 mg, qd	1 month	UAER ↓	No AEs	No AEs	
Liu et al. [54]	Mogensen III	28/28	67.0/67.5	7.3/7.2	Injection, 40 mL, qd	Irbesartan 150 mg, qd	4 weeks	Scr, UAER ↓	NS	NS	
Li and Zhang [55]	Mogensen III-IV	30/30	41.2/40.8	NS	Injection, 40 mL, qd	Benazepril 10 mg, qd	4 weeks	UAER ↓	NS	NS	
Kong [56]	NS	39/39	52.8/53.2	8.2/8.6	Injection, 20 mL, qd	Benazepril 10 mg, qd	3 weeks	Scr, BUN ↓	NS	NS	
Chen [57]	UAER>30 mg/24 h	50/50	63.15/63.23	6.32/6.25	Injection, 30 mL, qd	Telmisartan (dose not given)	2 weeks	Scr, BUN ↓	NS	NS	
Chen [58]	Mogensen III	34/34	48.89/49.06	7.65/8.26	Injection, 20 mL, qd	Conventional therapy	4 weeks	UAER ↓	NS	NS	
Zhao [59]	NS	35/35	52.7/51.4	8.2/7.9	Injection, 1.5~1.8 mL/(kg·d)	Conventional therapy	2 months	Scr, BUN ↓	NS	NS	
Zhang [60]	Mogensen III	28/28	51.25/51.41	9.42/9.41	Injection, 60 mL, qd	Losartan 50 mg, qd	4 weeks	Scr, BUN, UAER ↓	NS	NS	
Zhang and Cao [61]	NS	30/30	55/59	9.0/8.5	Injection, 40 mL, qd	Benazepril 10 mg, qd	3 weeks	Scr, 24 h UP, mALB ↓	NS	NS	
Sun, Zhao, and Ding [62]	Mogensen III	38/38	52.63/51.84	6.1/5.9	Injection, 20 mL, qd	Telmisartan 40 mg, qd	2 weeks	UAER ↓	NS	NS	
Dou and Wang [63]	Mogensen III	24/24	51/54	12/11	Tablet, 2.2 g, bid	Valsartan 80 mg, qd	12 weeks	24 h UP ↓	NS	NS	
Deng et al. [64]	Mogensen III	36/30	80.02/78.02	NS	APS injection 250 mg, qd	Conventional therapy	3 weeks	UAER, 24 h UP, Cys-C ↓	NS	NS	
Chang et al. [65]	24 h UP>2 g	24/24	54.14/56.38	11.72/11.92	Granules, 4 g, bid	Tripterygium glycosides 20 mg, tid	12 weeks	24 h UP, serum ALB, CRP ↓	4.2%/25%	1 case of liver function damage	
Note: Symbols “↑” and “↓” represent increase and decrease, respectively.

Abbreviations: 24 h UP, 24-h urinary protein; β2-MG, β2-microglobulin; ALB, albumin; BUN, blood urea nitrogen; CRP, C-reactive protein; Cys-C, serum cystatin C; NAG, N-acetyl-β-D aminoglucosidase; mALB, microalbumin; Scr, serum creatinine; UACR, urinary albumin to creatinine ratio; UAER, urinary albumin excretion rate.

Table 2 Prevention mechanism of RA on diabetic nephropathy.

	Model class	Modeling method	Pharmacological effect	Targets	Ref.	
AS-IV	db/db mice	/	Ameliorate glomerular hypertrophy and mesangial hyperplasia, protect the podocytes, attenuate proteinuria, and protect renal function	Activate PPARγ-Klotho-FoxO1 axis and inhibit oxidative stress	Xing et al. [69]	
Mouse podocytes	HG	Protect the podocytes	
	
AS-I	SD rats	STZ	Reduce ECM deposition, alleviate GBM thickening, ameliorate mesangial hyperplasia, attenuate proteinuria, and reduce blood glucose	Downregulate hyperglycemia-oxidative stress-AGEs/TGF-β1 pathway and inhibit oxidative stress	Yin et al. [70]	
	
AS-IV	Male SD rats	STZ	Reduce ECM deposition, ameliorate mesangial hyperplasia, alleviate GBM thickening, protect the podocytes, and attenuate proteinuria	Inhibit MAPK/ERK pathway, upregulate TRPC6 expression, and inhibit oxidative stress	He et al. [71]	
	
AS-IV	C57BL/6J mice	STZ	Reverse the increase of glomerular surface area and expansion of mesangial matrix, alleviate podocyte apoptosis, upregulate nephrin and podocin expression, and alleviate renal injury and mitochondrial disorder	Ameliorate mitochondrial dysfunction by upregulating Nrf2-ARE/TFAM signaling	Shen et al. [72]	
Mouse podocytes	HG	Inhibit podocyte mitochondrial morphological alterations and podocyte apoptosis	
	
AS-IV	Male SD rats	STZ	Ameliorate mesangial hyperplasia, protect the podocytes, and attenuate proteinuria	Modulate caspase and Bcl-2 protein families and inhibit oxidative stress	Gui et al. [73]	
Mouse podocytes	HG	Protect the podocytes	
	
Calycosin	NRK-52E cells	HG	Recover cell viability and membrane damage	Regulate Sirt3/SOD2/caspase-3 signaling and inhibit oxidative stress	Jiang et al. [81]	
	
Calycosin	Male SD rats	STZ	Recover mitochondrial viability	Mitigated lipoperoxidation of the cell membrane and oxidative stress-triggered mitochondrial respiration dysfunction	Huang et al. [83]	
	
AS-I	Rat mesangial cells	HG	Reduce ECM deposition and decrease HbA1c levels	Increase activities of antioxidant enzymes, inhibit iNOS/TGF-β1 signaling, and inhibit oxidative stress	Yin et al. [74]	
	
AS-IV	Human mesangial cell	HG	Ameliorate mesangial hyperplasia and improve MC contractile function	Inhibit the NADPH oxidase/ROS/Akt/NF-κB pathway and inhibit oxidative stress	Sun et al. [75]	
	
AS-IV	NRK-52E cell	GA	Inhibited EMT	Increase activities of antioxidant enzymes and inhibit oxidative stress	Qi et al. [76]	
	
AS-IV	HK-2 cells	HG	Protect TECs from apoptosis	Regulate the Nrf2/ARE signaling pathway, modulate caspase and Bcl-2 protein families, and inhibit oxidative stress	Wang and Guo [77]	
	
AS-IV	Male SD rats	STZ	Inhibited EMT	Increase activities of antioxidant enzymes, inhibit Wnt/β-catenin pathway, and inhibit oxidative stress	Wang et al. [78]	
HK-2 cells	HG	Reduce ECM deposition	
	
AS-IV	HK-2 cells	PA	Reduce lipid deposition and protect TECs from apoptosis	Modulate caspase and Bcl-2 protein families and inhibit oxidative stress	Chen et al. [79]	
	
Calycosin and calycosin-7-O-β-D-glucoside	Rat mesangial cells	HG	Ameliorate mesangial hyperplasia	/	Tang et al. [80]	
Human glomerular endothelial cells	AGEs	Protect glomerular endothelial cells from apoptosis	
	
Calycosin	SD rats	High-fat diet/STZ	Ameliorate glomerular hypertrophy, reduce ECM deposition, and attenuate proteinuria	Inhibit IL-33/ST2 and Nrf2/ARE signaling and inhibit oxidative stress	Elsherbiny et al. [82]	
	
AS-IV	Male SD rats	STZ	Protect TECs from apoptosis, alleviate epithelial cell edema, alleviate GBM thickening, reduce ECM deposition, attenuate proteinuria, and protect renal function	Modulate caspase and Bcl-2 protein families and inhibit ER stress	Ju et al. [87]	
	
AS-IV	Male SD rats	STZ	Ameliorate mesangial hyperplasia, protect the podocytes, and attenuate proteinuria	Modulate Bcl-2 protein family, downregulate PERK-ATF4-CHOP pathway, and inhibit ER stress	Chen et al. [88]	
	
AS-IV	Male SD rats	STZ	Ameliorate mesangial hyperplasia and reduce ECM deposition	Modulate caspase protein family and inhibit ER stress	Wang et al. [89]	
Human podocytes	Tunicamycin	Protect the podocytes	
	
Calycosin	Male SD rats	STZ	Attenuate proteinuria, protect renal function, and alleviate interstitial collagen deposition and thickening of glomerular basement membranes	Modulated NF-κB/p65/NLRP3/TXNIP-mediated pyroptotic signaling	Yosri et al. [84]	
	
AS-IV	db/db mice	/	Attenuate proteinuria and improve renal structural changes such as mesangial proliferation, ECM deposition, podocyte foot process fusion, foot process widening, podocyte loss, and GBM thickening, accompanied by the upregulation of the podocyte markers podocin and synaptopodin	Inhibit NLRP3 inflammasome-mediated inflammation	Feng et al. [95]	
Mouse podocytes	HG	Inhibit cell pyroptotic and increase cell viability	
	
AS-IV	Male SD rats	STZ	Improve renal function, protect podocytes, and inhibit glomeruli pyroptosis	Increase klotho levels in serum and kidney tissue	He et al. [96]	
Mouse podocytes	HG	Inhibited pyroptosis of podocytes	Increase klotho expression via the inhibition of the NF-κB/NLRP3 axis	
	
Calycosin	db/db mice	/	Inhibit lipid ROS production, protect renal function, and alleviate tubular dilatation, loss of proximal tubule brush border, and collagen deposition	Upregulate GSH and GPX4 levels and downregulate NCOA4 expression	Huang et al. [98]	
HK-2 cells	HG	Inhibit lipid ROS production and ferroptosis-induced tubular injury and increase cell viability	
	
AS-IV	C57BL/6J mice	STZ	Protect the podocytes, ameliorate glomerular hypertrophy and mesangial hyperplasia, alleviate glomerulosclerosis, attenuate proteinuria, and protect renal function	Regulate AMPK and PI3K/AKT/mTOR signaling, inhibit ER stress, and enhance autophagy	Guo et al. [90]	
Mouse podocytes	HG	Protect the podocytes	
	
AS-IV	db/db mice	/	Ameliorate glomerular hypertrophy and mesangial hyperplasia, protect the podocytes, attenuate proteinuria, protect renal function, normalize glucose tolerance and insulin sensitivity, and alleviate hypertension	Modulate caspase and Bcl-2 protein families and inhibit ER stress	Guo et al. [91]	
Mouse podocytes	PA	Protect the podocytes	
	
AS-IV	Male KKAy mice	High-fat diet	Ameliorate mesangial hyperplasia and reduce ECM deposition	Inhibit NF-κB pathway, anti-inflammation, and upregulate autophagy-related proteins	Wang et al. [100]	
Mouse glomerular mesangial cells	HG	Reduce ECM deposition and ameliorate mesangial hyperplasia	
	
AS-IV	Male SD rats	STZ	Reduce ECM deposition, ameliorate mesangial hyperplasia, protect the podocytes, and attenuate proteinuria	Inhibit NF-κB pathway, anti-inflammation	Gui et al. [102]	
	
APS	SD rats	STZ	Protect renal function and ameliorate mesangial cell hyperplasia and glomerular basement membrane thickening	Inhibit TLR4/NF-κB pathway, anti-inflammation	Guo et al. [103]	
MPC5 cells	HG	Alleviate podocyte proliferation	
	
APS	SD rats	STZ	/	Inhibit NF-κB pathway, anti-inflammation	Zhang, Wu, and Cheng [104]	
	
Calycosin	db/db mice	/	Reduce ECM deposition and alleviate GBM thickening and glomerular sclerosis	Inhibit NF-κB pathway, anti-inflammation	Zhang et al. [105]	
Mouse tubular epithelial cells	AGEs	/	
	
Astragalosides	MCs	HG	Reduce ECM deposition and ameliorate mesangial hyperplasia	Regulate TGF-β1/Smad signaling	Chen et al. [113]	
	
AS-IV	SD rats	STZ	Reduce ECM deposition and alleviate GBM thickening and glomerular atrophy	Modulate the TGF-β1/Smad/miR-192 signaling pathway, antifibrosis	Mao et al. [114]	
Rat MCs	HG	Ameliorate mesangial hyperplasia	
	
AS-IV	Male KKAy mice	High-fat diet	Protect the podocytes, alleviate GBM thickening, reduce ECM deposition, antifibrosis, and attenuate proteinuria	Regulate TGF-β1/Smad signaling, antifibrosis	Wang et al. [115]	
Mouse MCs	HG		
	
AS-IV	Human tubular endothelial cells	HG	Protect TECs from apoptosis	Regulate TGF-β1/Smads and p38/MAPK signaling, antifibrosis	Wang et al. [116]	
	
AS-IV	HK-2 cells	HG	Reduce ECM deposition and inhibit tubular EMT	Inhibit mTORC1/p70S6K signaling, antifibrosis	Chen et al. [117]	
	
AS-IV	Mouse renal fibroblasts	TGF-β1	Reduce ECM deposition and decrease fibroblast viability	Inhibit the MAPK and NF-κB signaling pathways, antifibrosis	Che et al. [118]	
	
Astragaloside	Male KKAy mice	High-fat diet	Ameliorate mesangial hyperplasia, alleviate TEC cytoplasm vacuole degeneration, and reduce renal interstitial inflammatory cells	Regulate TGF-β1/Smad signaling, antifibrosis	Wang et al. [119]	
	
AS-IV	db/db mice	/	Attenuate proteinuria, protect renal function, and improve proximal renal tubular cell swollen, renal tubular epithelial cells vacuolated, collagen deposition, glomerular hypertrophy, and mesangial matrix expansion	Decrease the expression of CX3CL1 and inhibit the activation of the RAF/MEK/ERK pathway	Hu et al. [112]	
HK-2 cells	HG	Suppress vimentin and α-SMA expression, increase E-cadherin expression, and suppress EMT	
	
AS-IV	Male C57BL/6 mice	STZ	Ameliorate mesangial hyperplasia, protect the podocytes, attenuate proteinuria, and protect renal function	Inhibit MEK1/2-ERK1/2-RSK2 signaling, antifibrosis	Song et al. [120]	
	
AS-IV	db/db mice	/	Alleviate GBM and TGM thickening, protect the podocytes, reduce ECM deposition, and attenuate proteinuria	Inhibit AKT/mTOR, NF-κB, and MAPK/ERK pathways, antifibrosis	Sun et al. [121]	
	
AS-IV	Male SD rats	STZ	Reduce ECM deposition, attenuate proteinuria, protect renal function, and decrease HbA1c levels	Activate eNOS and NO	Fan et al. [123]	
HRGECs	HG	Protect glomerular endothelial cells from apoptosis	
	
AS-IV	Mouse podocyte cells	HG	Protect the podocytes	Upregulate α3β1 integrin and inhibit ILK	Chen et al. [124]	
	
AS-IV	Male SD rats	STZ	Protect the podocytes and attenuate proteinuria	Upregulate α3β1 integrin and inhibit ILK	Chen et al. [125]	
	
AS-IV	Mouse podocytes	HG	Protect the podocytes	Downregulate TRPC6 and modulate Bcl-2 protein family	Yao et al. [126]	
	
AS-IV	Sprague–Dawley rats	STZ	Protect the podocytes, attenuate proteinuria, protect renal function, and reduce blood glucose and arterial blood pressure	Regulate miR-378/TRAF5 signaling pathway	Lei et al. [128]	
MPC5 cells	HG	Protect the podocytes	
	
AS-IV	Sprague–Dawley rats	STZ	Attenuate proteinuria	Regulate lncRNA-TUG1/TRAF5 signaling pathway and modulate caspase protein family	Lei et al. [129]	
MPC5 cells	HG	Protect the podocytes	
	
AS-IV	db/db mice	/	Ameliorate mesangial hyperplasia and attenuate proteinuria	Inhibit PINK1/Parkin-mediated mitophagy and modulate the mitochondrial quality control network	Liu et al. [135]	
Abbreviations: α-SMA, α-smooth muscle actin; AGEs, advanced glycation end products; Akt, protein kinase B; AMPK, adenosine 5′-monophosphate (AMP)-activated protein kinase; APSs, astragalus polysaccharides; AS-IV, astragaloside IV; ATF4/6, activating transcription factor 4/6; Bcl-2, B-cell lymphoma-2; Caspase, cysteinyl aspartate specific proteinase; CHOP, C/EBP-homologous protein; CX3CL1, chemokine C-X3-C-motif ligand 1; ECM, extracellular matrix; EMT, epithelial-mesenchymal transition; eNOS, endothelial nitric oxide synthase; ERK, extracellular signal-regulated kinase; ER stress, endoplasmic reticulum stress; FoxO1, forkhead box transcription factor O1; GA, glycosylated albumin; GBM, glomerular basement membrane; GPX4, phospholipid peroxidase glutathione peroxidase 4; GSH, glutathione; HbA1c, glycosylated hemoglobin; HFD, high-fat diet; HRGECs, human renal glomerular endothelial cells; iNOS, inducible nitric oxide synthase; LK, integrin-linked kinase; lncRNA-TUG1, long noncoding RNA taurine upregulated 1; MAPK, mitogen-activated protein kinase; MCs, mesangial cells; MEK1/2, mitogen-activated protein kinase kinase 1/2; miR-21/192/378, microRNA 21/192/378; MPC5 cells, murine podocyte cell line; mTOR, mammalian target of rapamycin; NADPH, nicotinamide adenine dinucleotide phosphate; NCOA4, nuclear receptor coactivator 4; NF-κB, nuclear factor-κB; NLRP3, NOD-like receptor thermal protein domain associated protein 3; NO, nitric oxide; Nrf2, NF-E2-related factor 2; PA, palmitic acid; PERK, protein kinase R (PKR)-like endoplasmic reticulum kinase; PINK1, PTEN-induced putative kinase 1; PI3K, phosphatidylinositol 3-kinase; PPARγ, peroxisome proliferators-activated receptor γ; RAF, Raf protein kinase; ROS, reactive oxygen species; RSK2, ribosomal protein S6 kinase 90 kDa polypeptide 3; SIRT1/3, sirtuin1/3; Smad, drosophila mothers against decapentaplegic protein; SOD, superoxide dismutase; TECs, tubular epithelial cells; TFAM, mitochondrial transcription factor A; TGF-β, transforming growth factor-β; TLR4, Toll-like receptor 4; TRAF2/5, TNF receptor–associated factor 2/5; TRPC6, transient receptor potential channel-6; TXNIP, thioredoxin-interacting protein.
==== Refs
1 Feehally J. Floege J. Tonelli M. Johnson R. J. Comprehensive clinical nephrology 2019 Sixth Edition Elsevier
2 Tervaert T. W. C. Mooyaart A. L. Amann K. Pathologic classification of diabetic nephropathy Journal of the American Society of Nephrology 2010 21 4 556 563 10.1681/ASN.2010010010 2-s2.0-77950601556 20167701
3 Umanath K. Lewis J. B. Update on diabetic nephropathy: core curriculum 2018 American Journal of Kidney Diseases 2018 71 6 884 895 10.1053/j.ajkd.2017.10.026 2-s2.0-85041598344 29398179
4 American Diabetes Association Professional Practice Committee 11. Chronic kidney disease and risk management: standards of care in diabetes-2024 Diabetes Care 2024 47 Supplement_1 S219 S230 10.2337/dc24-S011 38078574
5 Lu Z. Zhong Y. Liu W. Xiang L. Deng Y. The efficacy and mechanism of Chinese herbal medicine on diabetic kidney disease Journal Diabetes Research 2019 2019 1, article 2697672 10.1155/2019/2697672 2-s2.0-85072397335
6 Fu J. Wang Z. Huang L. Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi) Phytotherapy Research 2014 28 9 1275 1283 10.1002/ptr.5188 2-s2.0-84907922943 25087616
7 Chu C. Qi L.-W. Liu E.-H. Li B. Gao W. Li P. Radix Astragali (Astragalus): latest advancements and trends in chemistry, analysis, pharmacology and pharmacokinetics COC 2010 14 16 1792 1807 10.2174/138527210792927663 2-s2.0-78649969476
8 Zhang J. Wu C. Gao L. Du G. Qin X. Astragaloside IV derived from Astragalus membranaceus: a research review on the pharmacological effects Advances in Pharmacology 2020 87 89 112 10.1016/bs.apha.2019.08.002 32089240
9 Ren S. Zhang H. Mu Y. Sun M. Liu P. Pharmacological effects of astragaloside IV: a literature review Journal of Traditional Chinese Medicine 2013 33 3 413 416 10.1016/S0254-6272(13)60189-2 24024343
10 Zheng Y. Ren W. Zhang L. Zhang Y. Liu D. Liu Y. A review of the pharmacological action of astragalus polysaccharide Frontiers in Pharmacology 2020 11 p. 349 10.3389/fphar.2020.00349 32265719
11 Deng M. Chen H. Long J. Song J. Xie L. Li X. Calycosin: a review of its pharmacological effects and application prospects Expert Review of Anti-Infective Therapy 2021 19 7 911 925 10.1080/14787210.2021.1863145 33346681
12 Gao J. Liu Z. J. Chen T. Zhao D. Pharmaceutical properties of calycosin, the major bioactive isoflavonoid in the dry root extract of Radix astragali Pharmaceutical Biology 2014 52 9 1217 1222 10.3109/13880209.2013.879188 2-s2.0-84906066717 24635389
13 Li M. Wang W. Xue J. Gu Y. Lin S. Meta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy Journal of Ethnopharmacology 2011 133 2 412 419 10.1016/j.jep.2010.10.012 2-s2.0-78651402015 20951192
14 Zhang L. Shergis J. L. Yang L. Astragalus membranaceus (Huang Qi) as adjunctive therapy for diabetic kidney disease: an updated systematic review and meta-analysis Journal of Ethnopharmacology 2019 239, article 111921 10.1016/j.jep.2019.111921 2-s2.0-85065143493 31034954
15 Guo J. C.-L. Pan H.-C. Yeh B.-Y. Associations between using Chinese herbal medicine and long-term outcome among pre-dialysis diabetic nephropathy patients: a retrospective population-based cohort study Frontiers in Pharmacology 2021 12 p. 616522 10.3389/fphar.2021.616522 33679399
16 Chen X. Sheng D. Kong X. Shao G. Clinical observation and mechanism of hydroxychloroquine combined with Astragalus tablet in the treatment of diabetic nephropathy Chinese Journal of Integrated Traditional and Western Nephrology 2023 24 1 39 41
17 Zhang X. Yang J. Mao Q. Huang J. Wang C. Effects of astragalus polysaccharide on renal function, neutrophil/lymphocyte ratio, Th1, Th2 and Th1/Th2 values in patients with diabetic nephropathy China’s Naturopathy 2022 30 6 80 82
18 Wang J. Liu Y. Guo H. Effect of Astragalus on improving urinary L-FABP in patients with early type 2 diabetic nephropathy Hunan Journal Of Traditional Chinese Medicine 2022 38 10 22 26
19 Liu J. Observation on the effect of Astragalus membranaceus in treating patients with diabetic nephropathy Modern Diagnosis and Treatment 2022 33 1 21 24
20 Zhou G. Li Y. Peng Y. Yang Y. Cui J. Lv Q. Effects of astragalus polysaccharide injection on the levels of urine CXCL10, E-cadherin and MMP-9 in patients with diabetic nephropathy Medical & Pharmaceutical Journal of Chinese People’s Liberation Army 2021 33 1 94 107
21 Sheng D. Chen X. Efficacy of Astragalus tablet combined with irbesartan in the treatment of early diabetic nephropathy and its effect on serum MCP-1 and TNF-α levels China Modern Doctor 2021 59 24 58 61
22 Han Y. Effectiveness of Astragalus injection in diabetes nephropathy Continuing Medical Education 2020 34 11 163 165
23 Xu A. Study on the effect and value of Astragalus injection in the treatment of diabetes nephropathy Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine 2019 19 3 73 75
24 Sun T. Effect of Astragalus injection combined with calcium dobesilate on renal function and ADL score in patients with diabetes nephropathy Journal of Practical Diabetology 2019 15 5 50 51
25 Chen T. Wang Z. Wang D. Clinical effect of Astragalus membranaceus on diabetes nephropathy and its influence on urinary podocalyxin Chinese Journal of Integrated Traditional and Western Nephrology 2019 20 8 694 696
26 Xu F. Liu Y. Clinical efficacy of Astragalus injection combined with alprostadil in the treatment of early diabetic nephropathy Chinese Journal of Clinical Rational Drug Use 2018 11 20 11 12
27 Wang Y. Du G. Clinical study of Astragalus membranaceus combined with valsartan in the treatment of diabetic nephropathy Shenzhen Journal of Integrated Traditional Chinese and Western Medicine 2018 28 22 38 39
28 Wang S. Zhang X. Efficacy and safety of atorvastatin combined with Astragalus in treatment of patients with early-stage type-2 diabetic nephropathy China Journal of Modern Medicine 2018 28 13 85 90
29 Wang M. Clinical study of Huangqi injection combined with spironolactone in treatment of diabetic nephropathy Drugs & Clinic 2018 33 4 898 902
30 Sun P. Effects of Astragalus injection combined with valsartan on urinary protein, BUN, Scr and hemorheology in patients with diabetic nephropathy Modern Diagnosis and Treatment 2018 29 20 3211 3213
31 Qiao M. Clinical study of Astragalus injection in treatment of diabetic nephropathy Hubei Journal of Traditional Chinese Medicine 2018 40 4 10 12
32 Liu C. Chen J. Randomized controlled parallel study of Astragalus injection combined with zinc protamine recombinant insulin lispro in the treatment of early diabetic nephropathy Journal of Practical Traditional Chinese Internal Medicine 2018 32 8 45 48
33 Zhou J. Zhang H. Clinical observation of Astragalus injection in the treatment of diabetic nephropathy Journal of Hebei North University (Natural Science Edition) 2017 33 8 44 45
34 Zhang X. Effect of Astragalus injection combined with valsartan in treating diabetic nephropathy Contemporary Medical Symposium 2017 15 16 178 180
35 Wang J. Clinical effect of Astragalus granule combined with valsartan on early diabetic nephropathy Inner Mongolia Journal of Traditional Chinese Medicine 2017 36 17 56 57
36 Qi H. Clinical study of Astragalus membranaceus in the treatment of diabetic nephropathy Diabetes New World 2017 20 3 166 167
37 Li H. Xu Y. Effect of Huangqi injection in combined with irbesartan on the vascular endothelial function and CGRP in patients with early DN Journal of Hainan Medical University 2017 23 3 362 364
38 Li D. Effect of Astragalus injection combined with benazepril on proteinuria in diabetic nephropathy Diabetes New World 2017 20 12 167 168
39 He C. Luo X. Li J. Effect of Astragalus membranaceus combined with captopril on proteinuria in diabetic nephropathy Diabetes New World 2017 20 15 177 178
40 Zhang Y. Zhang H. The effect of Astragalus membranaceus on reducing microalbuminuria in diabetic nephropathy Diabetes New World 2016 19 18 22 23
41 Xiang Y. Clinical observation of early diabetic nephropathy treated with valsartan and Huangqi granules World Journal of Integrated Traditional and Western Medicine 2016 11 10 1444 1446
42 Tang H. Effect of valsartan combined with Astragalus injection on early diabetic nephropathy China Medical Engineering 2016 24 10 40 41
43 Ren Y. Effect of Huangqi injection in combined with irbesartan on the microcirculation and CTGF in patients with early DN Journal of Hainan Medical University 2016 22 22 2696 2702
44 Liu S. Deng X. Astragalus membranaceus combined with valsartan in the treatment of diabetic nephropathy and its effect on urinary leucinearylamidase and podocalyxin levels China Journal of Modern Medicine 2016 26 15 102 105
45 Li X. Clinical effect of Astragalus injection combined with enalapril on diabetic nephropathy Chinese Journal of Clinical Rational Drug Use 2016 9 21 95 96
46 Fang W. Ma J. Li Q. Cai X. Su H. Effect of Alprostadil combined with Astragalus injection on edema in diabetic nephropathy Journal of Guangxi Medical University 2016 33 5 889 891
47 Cai R. Cui J. Effect of Astragalus injection on urinary albumin and cytokines in patients with early diabetic nephropathy Modern Journal of Integrated Traditional Chinese and Western Medicine 2016 25 28 3117 3119
48 Xiao B. Liu Y. Clinical observation of alprostadil injection combined with Astragalus injection in the treatment of early diabetic nephropathy Chinese Journal of Clinical Rational Drug Use 2015 8 20 5 6
49 Wang X. Effects of irbesartan combined with Astragalus injection treatment on microcirculation dysfunction and oxidative stress index in elderly patients with diabetic nephropathy Journal of Hainan Medical University 2015 21 12 1636 1639
50 Shi G. Lin S. Effect of Astragalus injection on the clinical symptoms and urinary microalbumin in patients with early diabetic nephropathy Military Medicine of Joint Logistics 2015 29 2 111 129
51 Ouyang H. Clinical study of Astragalus injection combined with atorvastatin calcium in the treatment of diabetic nephropathy Journal of China Prescription Drug 2015 13 8 5 7
52 Luo X. Safety analysis and efficacy of treating diabetic nephropathy with Astragalus membranaceus Clinical Journal of Chinese Medicine 2015 7 8 29 30
53 Liu X. Meng X. Wei N. Effects of Astragalus membranaceus on endothelin and calcitonin gene-related peptide in patients with early diabetic nephropathy Chinese Journal of Gerontology 2015 35 8 2059 2061
54 Liu S. Zhang M. Yang X. Liu L. Effect of irbesartan combined with Astragalus injection on connective tissue growth factor in elderly diabetic nephropathy patients Chinese Journal of Gerontology 2015 35 1 108 110
55 Li S. Zhang T. Clinical observation on 30 cases of diabetic nephropathy treated with Astragalus injection Modern Diagnosis and Treatment 2015 26 21 4869 4870
56 Kong W. Clinical study of Astragalus injection in the treatment of diabetic nephropathy Pharmacology and Clinics of Chinese Materia Medica 2015 31 2 102 103
57 Chen S. Clinical observation on treatment of diabetic nephropathy with Astragalus Diabetes New World 2015 11 27 29
58 Chen H. Clinical study of Astragalus injection in the treatment of proteinuria in early diabetic nephropathy Diabetes New World 2015 8 32 34
59 Zhao L. Clinical observation of high-dose Astragalus injection in the treatment of chronic renal failure in diabetic nephropathy Guide of China Medicine 2014 12 11 281 282
60 Zhang Q. Effect of losartan combined with Astragalus injection on early diabetic nephropathy Jilin Medical Journal 2014 35 10 2146 2147
61 Zhang D. Cao G. Astragalus injection in treatment 30 cases of diabetic nephropathy Chinese Medicine Modern Distance Education of China 2014 12 7 103 165
62 Sun Y. Zhao F. Ding X. Clinical observation of early diabetic nephropathy treated with temisartan and Astragalus injection Chinese Journal of Integrated Traditional and Western Nephrology 2014 15 9 799 800
63 Dou C. Wang S. Astragalus tablet combined with valsartan in the treatment of 24 cases of early diabetic nephropathy Traditional Chinese Medicinal Research 2014 27 2 29 31
64 Deng H. Lin K. Li Y. Zhi X. Wu W. Effect of astragalus polysaccharides on TNF- α, IL-6, and immune function in elderly patients with early diabetes nephropathy Journal of Chinese Medicinal Materials 2014 37 4 713 716
65 Chang B. Chen W. Zhang Y. Bi Y. Liu L. Zhang J. Clinical effects of Tripterygium glycosides combined with Astragalus granules in the treatment for diabetic nephropathy Chinese Traditional Patent Medicine 2014 36 9 1827 1830
66 Chen P.-S. Li Y.-P. Ni H.-F. Morphology and evaluation of renal fibrosis Advances in Experimental Medicine and Biology 2019 1165 17 36 10.1007/978-981-13-8871-2_2 2-s2.0-85071282629 31399959
67 Daenen K. Andries A. Mekahli D. Van Schepdael A. Jouret F. Bammens B. Oxidative stress in chronic kidney disease Pediatric Nephrology 2019 34 6 975 991 10.1007/s00467-018-4005-4 2-s2.0-85051674288 30105414
68 Zhang L. Wen Z. Han L. Research progress on the pathological mechanisms of podocytes in diabetic nephropathy Journal of Diabetes Research 2020 2020 15 10.1155/2020/7504798 7504798
69 Xing L. Fang J. Zhu B. Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy Life Sciences 2021 269, article 119068 10.1016/j.lfs.2021.119068 33476631
70 Yin X. Zhang Y. Wu H. Protective effects of Astragalus saponin I on early stage of diabetic nephropathy in rats Journal of Pharmacological Sciences 2004 95 2 256 266 10.1254/jphs.FP0030597 2-s2.0-3142586947 15215651
71 He K. Li W. Chai X. Yin Y. Jiang Y. Li W. Astragaloside IV prevents kidney injury caused by iatrogenic hyperinsulinemia in a streptozotocin-induced diabetic rat model International Journal of Molecular Medicine 2017 41 2 1078 1088 10.3892/ijmm.2017.3265 2-s2.0-85040452734 29207011
72 Shen Q. Fang J. Guo H. Astragaloside IV attenuates podocyte apoptosis through ameliorating mitochondrial dysfunction by up-regulated Nrf2-ARE/TFAM signaling in diabetic kidney disease Free Radical Biology & Medicine 2023 203 45 57 10.1016/j.freeradbiomed.2023.03.022 37030337
73 Gui D. Guo Y. Wang F. Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo Plos One 2021 7 6, article e39824 10.1371/journal.pone.0039824 2-s2.0-84862649935 22745830
74 Yin X. Zhang Y. Yu J. The antioxidative effects of Astragalus saponin I protect against development of early diabetic nephropathy Journal of Pharmacological Sciences 2006 101 2 166 173 10.1254/jphs.FP0050041 2-s2.0-33745305707 16766854
75 Sun L. Li W. Li W. Xiong L. Li G. Ma R. Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF-κB pathway under high glucose conditions International Journal of Molecular Medicine 2014 34 1 167 176 10.3892/ijmm.2014.1741 2-s2.0-84902653456 24718766
76 Qi W. Niu J. Qin Q. Qiao Z. Gu Y. Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells Cell Stress and Chaperones 2014 19 1 105 114 10.1007/s12192-013-0438-7 2-s2.0-84891147629 23719694
77 Wang J. Guo H.-M. Astragaloside IV ameliorates high glucose-induced HK-2 cell apoptosis and oxidative stress by regulating the Nrf2/ARE signaling pathway Experimental and Therapeutic Medicine 2019 17 6 4409 4416 10.3892/etm.2019.7495 31086575
78 Wang E. Wang L. Ding R. Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy Pharmacological Research 2020 157 p. 104831 10.1016/j.phrs.2020.104831 32339782
79 Chen Q. Su Y. Ju Y. Ma K. Li W. Li W. Astragalosides IV protected the renal tubular epithelial cells from free fatty acids-induced injury by reducing oxidative stress and apoptosis Biomedicine & Pharmacotherapy 2018 108 679 686 10.1016/j.biopha.2018.09.049 2-s2.0-85053557115 30245468
80 Tang D. He B. Zheng Z.-G. Inhibitory effects of two major isoflavonoids in Radix Astragali on high glucose-induced mesangial cells proliferation and AGEs-induced endothelial cells apoptosis Planta Medica 2011 77 7 729 732 10.1055/s-0030-1250628 2-s2.0-79955852776 21157685
81 Jiang R. Ge J. Zhao J. Yan X. The protective effects of calycosin against diabetic nephropathy through Sirt3/SOD2/caspase-3 signaling pathway: in vitro Arabian Journal of Chemistry 2021 14 3, article 102988 10.1016/j.arabjc.2021.102988
82 Elsherbiny N. M. Said E. Atef H. Zaitone S. A. Renoprotective effect of calycosin in high fat diet-fed/STZ injected rats: effect on IL-33/ST2 signaling, oxidative stress and fibrosis suppression Chemico-Biological Interactions 2020 315 p. 108897 10.1016/j.cbi.2019.108897 31726037
83 Huang C. Xue L.-F. Hu B. Calycosin-loaded nanoliposomes as potential nanoplatforms for treatment of diabetic nephropathy through regulation of mitochondrial respiratory function Journal of Nanobiotechnology 2021 19 1 p. 178 10.1186/s12951-021-00917-1 34120609
84 Yosri H. El-Kashef D. H. El-Sherbiny M. Said E. Salem H. A. Calycosin modulates NLRP3 and TXNIP-mediated pyroptotic signaling and attenuates diabetic nephropathy progression in diabetic rats; an insight Biomedicine & Pharmacotherapy 2022 155 p. 113758 10.1016/j.biopha.2022.113758 36271546
85 Cunard R. Sharma K. The endoplasmic reticulum stress response and diabetic kidney disease American Journal of Physiology-Renal Physiology 2011 300 5 F1054 F1061 10.1152/ajprenal.00021.2011 2-s2.0-79955752164 21345978
86 Cybulsky A. V. Endoplasmic reticulum stress, the unfolded protein response and autophagy in kidney diseases Nature Reviews. Nephrology 2017 13 11 681 696 10.1038/nrneph.2017.129 2-s2.0-85031743411 28970584
87 Ju Y. Su Y. Chen Q. Protective effects of astragaloside IV on endoplasmic reticulum stress-induced renal tubular epithelial cells apoptosis in type 2 diabetic nephropathy rats Biomedicine & Pharmacotherapy 2019 109 84 92 10.1016/j.biopha.2018.10.041 2-s2.0-85055896160 30396095
88 Chen Y. Gui D. Chen J. He D. Luo Y. Wang N. Down-regulation of PERK-ATF4-CHOP pathway by astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats Cellular Physiology and Biochemistry 2014 33 6 1975 1987 10.1159/000362974 2-s2.0-84903866014 25012492
89 Wang Z. S. Xiong F. Xie X. H. Chen D. Pan J. H. Cheng L. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress BMC Nephrology 2015 16 1 p. 44 10.1186/s12882-015-0031-7 2-s2.0-84926429363 25886386
90 Guo H. Wang Y. Zhang X. Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy Scientific Reports 2017 7 1 p. 6852 10.1038/s41598-017-07061-7 2-s2.0-85026656718 28761152
91 Guo H. Cao A. Chu S. Astragaloside IV attenuates podocyte apoptosis mediated by endoplasmic reticulum stress through upregulating sarco/endoplasmic reticulum Ca2+-ATPase 2 expression in diabetic nephropathy Frontiers in Pharmacology 2016 7 p. 500 10.3389/fphar.2016.00500 2-s2.0-85009224903
92 Sanz A. B. Sanchez-Niño M. D. Ramos A. M. Ortiz A. Regulated cell death pathways in kidney disease Nature Reviews. Nephrology 2023 19 5 281 299 10.1038/s41581-023-00694-0 36959481
93 Galluzzi L. Vitale I. Aaronson S. A. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 Cell Death & Differentiation 2018 25 3 486 541 10.1038/s41418-017-0012-4 2-s2.0-85036533976 29362479
94 Jorgensen I. Miao E. A. Pyroptotic cell death defends against intracellular pathogens Immunological Reviews 2015 265 1 130 142 10.1111/imr.12287 2-s2.0-84927745897 25879289
95 Feng H. Zhu X. Tang Y. Fu S. Kong B. Liu X. Astragaloside IV ameliorates diabetic nephropathy in db/db mice by inhibiting NLRP3 inflammasome-mediated inflammation International Journal of Molecular Medicine 2021 48 2 p. 164 10.3892/ijmm.2021.4996 34278447
96 He J. Cui J. Shi Y. Astragaloside IV attenuates high-glucose-induced impairment in diabetic nephropathy by increasing klotho expression via the NF-κB/NLRP3 axis Journal Diabetes Research 2023 2023, article 7423661 10.1155/2023/7423661
97 Stockwell B. R. Friedmann Angeli J. P. Bayir H. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease Cell 2017 171 2 273 285 10.1016/j.cell.2017.09.021 2-s2.0-85030552365 28985560
98 Huang D. Shen P. Wang C. Gao J. Ye C. Wu F. Calycosin plays a protective role in diabetic kidney disease through the regulation of ferroptosis Pharmaceutical Biology 2022 60 1 990 996 10.1080/13880209.2022.2067572 35587919
99 Koch E. A. T. Nakhoul R. Nakhoul F. Nakhoul N. Autophagy in diabetic nephropathy: a review International Urology and Nephrology 2020 52 9 1705 1712 10.1007/s11255-020-02545-4 32661628
100 Wang X. Gao Y. Tian N. Astragaloside IV represses high glucose-induced mesangial cells activation by enhancing autophagy via SIRT1 deacetylation of NF-κB P65 subunit Drug Design Development and Therapy 2018 Volume 12 2971 2980 10.2147/DDDT.S174058 2-s2.0-85057811979 30254426
101 Xie W. Du L. Diabetes is an inflammatory disease: evidence from traditional Chinese medicines Diabetes, Obesity & Metabolism 2011 13 4 289 301 10.1111/j.1463-1326.2010.01336.x 2-s2.0-79951931336
102 Gui D. Huang J. Guo Y. Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression Cytokine 2013 61 3 970 977 10.1016/j.cyto.2013.01.008 2-s2.0-84875378096 23434274
103 Guo M. Gao J. Jiang L. Dai Y. Astragalus polysaccharide ameliorates renal inflammatory responses in a diabetic nephropathy by suppressing the TLR4/NF-κB pathway Drug Design, Development and Therapy 2023 Volume 17 2107 2118 10.2147/DDDT.S411211 37489175
104 Zhang Y.-W. Wu C.-Y. Cheng J.-T. Merit of astragalus polysaccharide in the improvement of early diabetic nephropathy with an effect on mRNA expressions of NF-κB and IκB in renal cortex of streptozotoxin-induced diabetic rats Journal of Ethnopharmacology 2007 114 3 387 392 10.1016/j.jep.2007.08.024 2-s2.0-35648986644 17900838
105 Zhang Y.-Y. Tan R.-Z. Zhang X.-Q. Yu Y. Yu C. Calycosin ameliorates diabetes-induced renal inflammation via the NF-κB pathway in vitro and in vivo Medical Science Monitor 2019 25 1671 1678 10.12659/MSM.915242 2-s2.0-85062410236 30830898
106 Huang R. Fu P. Ma L. Kidney fibrosis: from mechanisms to therapeutic medicines Signal Transduction and Targeted Therapy 2023 8 1 p. 129 10.1038/s41392-023-01379-7 36932062
107 Cao Y. Yang Z. Chen Y. An overview of the posttranslational modifications and related molecular mechanisms in diabetic nephropathy Frontiers in Cell and Developmental Biology 2021 9 10.3389/fcell.2021.630401 34124032
108 Zeng L. F. Xiao Y. Sun L. A glimpse of the mechanisms related to renal fibrosis in diabetic nephropathy Advances in Experimental Medicine and Biology 2019 1165 49 79 10.1007/978-981-13-8871-2_4 2-s2.0-85071282320 31399961
109 Djudjaj S. Boor P. Cellular and molecular mechanisms of kidney fibrosis Molecular Aspects of Medicine 2019 65 16 36 10.1016/j.mam.2018.06.002 2-s2.0-85048871840 29909119
110 Romagnani P. Remuzzi G. Glassock R. Chronic kidney disease Nature Reviews Disease Primers 2017 3 1 p. 17088 10.1038/nrdp.2017.88 2-s2.0-85035241193
111 Humphreys B. D. Mechanisms of renal fibrosis Annual Review of Physiology 2018 80 1 309 326 10.1146/annurev-physiol-022516-034227 2-s2.0-85041909001
112 Hu Y. Tang W. Liu W. Hu Z. Pan C. Astragaloside IV alleviates renal tubular epithelial-mesenchymal transition via CX3CL1-RAF/MEK/ERK signaling pathway in diabetic kidney disease Drug Design, Development and Therapy 2022 Volume 16 1605 1620 10.2147/DDDT.S360346 35669284
113 Chen X. Wang D.-D. Wei T. He S.-M. Zhang G.-Y. Wei Q.-L. Effects of astragalosides from Radix Astragali on high glucose-induced proliferation and extracellular matrix accumulation in glomerular mesangial cells Experimental and Therapeutic Medicine 2016 11 6 2561 2566 10.3892/etm.2016.3194 2-s2.0-84964091240 27313676
114 Mao Q. Chen C. Liang H. Zhong S. Cheng X. Li L. Astragaloside IV inhibits excessive mesangial cell proliferation and renal fibrosis caused by diabetic nephropathy via modulation of the TGF-β1/Smad/miR-192 signaling pathway Experimental and Therapeutic Medicine 2019 18 4 3053 3061 10.3892/etm.2019.7887 31572545
115 Wang X. Gao Y. Tian N. Zou D. Shi Y. Zhang N. Astragaloside IV improves renal function and fibrosis via inhibition of miR-21-induced podocyte dedifferentiation and mesangial cell activation in diabetic mice Drug Design Development and Therapy 2018 Volume 12 2431 2442 10.2147/DDDT.S170840 2-s2.0-85057277642 30122901
116 Wang Q. Shao X. Xu W. Astragalosides IV inhibits high glucose-induced cell apoptosis through HGF activation in cultured human tubular epithelial cells Renal Failure 2014 36 3 400 406 10.3109/0886022X.2013.867798 2-s2.0-84896473250 24392874
117 Chen X. Yang Y. Liu C. Chen Z. Wang D. Astragaloside IV ameliorates high glucose-induced renal tubular epithelial-mesenchymal transition by blocking mTORC1/p70S6K signaling in HK-2 cells International Journal of Molecular Medicine 2019 43 2 709 716 10.3892/ijmm.2018.3999 2-s2.0-85060032439 30483732
118 Che X. Wang Q. Xie Y. Astragaloside IV suppresses transforming growth factor-β1 induced fibrosis of cultured mouse renal fibroblasts via inhibition of the MAPK and NF-κB signaling pathways Biochemical and Biophysical Research Communications 2015 464 4 1260 1266 10.1016/j.bbrc.2015.07.116 2-s2.0-84940459688 26220342
119 Wang Y. Lin C. Ren Q. Liu Y. Yang X. Astragaloside effect on TGF-β1, SMAD2/3, and α-SMA expression in the kidney tissues of diabetic KKAy mice International Journal of Clinical and Experimental Pathology 2015 8 6 6828 6834 26261569
120 Song G. Han P. Sun H. Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice The Journal of International Medical Research 2018 46 7 2883 2897 10.1177/0300060518778711 2-s2.0-85050395845 29896981
121 Sun H. Wang W. Han P. Astragaloside IV ameliorates renal injury in db/db mice Scientific Reports 2016 6 1 p. 32545 10.1038/srep32545 2-s2.0-84986197758 27585918
122 Tabit C. E. Chung W. B. Hamburg N. M. Vita J. A. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications Reviews in Endocrine & Metabolic Disorders 2010 11 1 61 74 10.1007/s11154-010-9134-4 2-s2.0-77953393648 20186491
123 Fan Y. Fan H. Zhu B. Zhou Y. Liu Q. Li P. Astragaloside IV protects against diabetic nephropathy via activating eNOS in streptozotocin diabetes-induced rats BMC Complementary and Alternative Medicine 2019 19 1 p. 355 10.1186/s12906-019-2728-9 31805910
124 Chen J. Gui D. Chen Y. Mou L. Liu Y. Huang J. Astragaloside IV improves high glucose-induced podocyte adhesion dysfunction via α3β1 integrin upregulation and integrin-linked kinase inhibition Biochemical Pharmacology 2008 76 6 796 804 10.1016/j.bcp.2008.06.020 2-s2.0-50649092654 18652804
125 Chen J. Chen Y. Luo Y. Gui D. Huang J. He D. Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats European Journal of Pharmacology 2014 736 86 94 10.1016/j.ejphar.2014.04.037 2-s2.0-84900354178 24809932
126 Yao X.-M. Liu Y.-J. Wang Y.-M. Astragaloside IV prevents high glucose-induced podocyte apoptosis via downregulation of TRPC6 Molecular Medicine Reports 2016 13 6 5149 5156 10.3892/mmr.2016.5167 2-s2.0-84966470331 27109610
127 Wu F. Yao D.-S. Lan T.-Y. Berberine prevents the apoptosis of mouse podocytes induced by TRAF5 overexpression by suppressing NF-κB activation International Journal of Molecular Medicine 2018 41 1 555 563 29115406
128 Lei X. Zhang B. Ren J.-G. Luo F.-L. Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378/TRAF5 signaling pathway Life Sciences 2018 206 77 83 10.1016/j.lfs.2018.05.037 2-s2.0-85047263717 29792879
129 Lei X. Zhang L. Li Z. Ren J. Astragaloside IV/lncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats Drug Design, Development and Therapy 2018 Volume 12 2785 2793 10.2147/DDDT.S166525 2-s2.0-85057774709 30233141
130 Begum M. Choubey M. Tirumalasetty M. B. Adiponectin: a promising target for the treatment of diabetes and its complications Life 2023 13 11 p. 2213 10.3390/life13112213 38004353
131 Dai W. Choubey M. Patel S. Singer H. A. Ozcan L. Adipocyte CAMK2 deficiency improves obesity-associated glucose intolerance Molecular Metabolism 2021 53, article 101300 10.1016/j.molmet.2021.101300 34303021
132 Singh A. Choubey M. Bora P. Krishna A. Adiponectin and chemerin: contrary adipokines in regulating reproduction and metabolic disorders Reproductive Sciences 2018 25 10 1462 1473 10.1177/1933719118770547 2-s2.0-85045850429 29669464
133 Kim Y. Lim J. H. Kim M. Y. The adiponectin receptor agonist AdipoRon ameliorates diabetic nephropathy in a model of type 2 diabetes JASN 2018 29 4 1108 1127 10.1681/ASN.2017060627 2-s2.0-85044788804 29330340
134 Xu A. Wang H. Hoo R. L. C. Selective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerance in obese mice Endocrinology 2009 150 2 625 633 10.1210/en.2008-0999 2-s2.0-59649117072 18927219
135 Liu X. Wang W. Song G. Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network PLoS ONE 2017 12 8, article e0182558 10.1371/journal.pone.0182558 2-s2.0-85026785554 28767702
136 Zhang C.-H. Yang X. Wei J.-R. Ethnopharmacology, phytochemistry, pharmacology, toxicology and clinical applications of Radix Astragali Chinese Journal of Integrative Medicine 2021 27 229 240 31502185
137 Li X. Qu L. Dong Y. A review of recent research progress on the Astragalus genus Molecules 2014 19 11 18850 18880 10.3390/molecules191118850 2-s2.0-84914703161 25407722
138 Fang J. Du W. Overview on the substance of qi deficiency syndrome of traditional Chinese medicine theory Lishizhen Medicine and Materia Medica Research 2016 27 2 430 432
139 Zhou P. Xie W. He S. Ginsenoside Rb1 as an anti-diabetic agent and its underlying mechanism analysis Cells 2019 8 3 p. 204 10.3390/cells8030204 30823412
140 Tt H. Nd K. Yr P. Sj O. My L. Kw K. Ginsenoside Rg3 increases nitric oxide production via increases in phosphorylation and expression of endothelial nitric oxide synthase: essential roles of estrogen receptor-dependent PI3-kinase and AMP-activated protein kinase Toxicology and Applied Pharmacology 2010 246 3 171 183 10.1016/j.taap.2010.05.008 2-s2.0-77956886889 20546771
141 Ahmed A. Zeng G. Azhar M. Jiawei Shengmai San herbal formula ameliorates diabetic associate cognitive decline by modulating AKT and CREB in rats Phytotherapy Research 2020 34 12 3249 3261 10.1002/ptr.6773 32619059
142 Yang J. Li J. Li L. Mechanism of herbal pairs with the properties of qi-tonifying, blood activation, blood-stasis breaking in treating coronary heart disease Journal of Traditional Chinese Medicine 2017 37 2 269 278 10.1016/S0254-6272(17)30054-7 29961275
143 Zhang F. Liu Y. Zheng S. Dang B. Wang J. Zhang Z. Pharmacological network reveals the active mechanism of qi-replenishing, spleen-strengthening, phlegm-dispelling, and blood-nourishing Fufang on coronary heart disease Evidence-based Complementary and Alternative Medicine 2020 2020 1 1062325 10.1155/2020/1062325 33456482
144 Li F.-H. Guo S.-W. Zhan T.-W. Integrating network pharmacology and experimental evidence to decipher the cardioprotective mechanism of Yiqihuoxue decoction in rats after myocardial infarction Journal of Ethnopharmacology 2021 279, article 114062 10.1016/j.jep.2021.114062 33771641
145 Zhang W. Lv M. Shi Y. Mu Y. Yao Z. Yang Z. Network pharmacology-based study of the underlying mechanisms of Huangqi Sijunzi decoction for Alzheimer’s disease Evidence-based Complementary and Alternative Medicine 2021 2021 1 6480381 10.1155/2021/6480381
146 Tian J. Huang Y. Wu T. The use of Chinese Yang/Qi-invigorating tonic botanical drugs/herbal formulations in ameliorating chronic kidney disease by enhancing mitochondrial function Frontiers in Pharmacology 2021 12, article 622498 10.3389/fphar.2021.622498 34248614
147 American Diabetes Association Professional Practice Committee 10. Cardiovascular disease and risk management: standards of care in diabetes-2024 Diabetes Care 2024 47 Supplement_1 S179 S218 10.2337/dc24-S010 38078592
148 Li S. Vandvik P. O. Lytvyn L. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline BMJ 2021 373 p. n1091 10.1136/bmj.n1091 33975892
149 de Boer I. H. Khunti K. Sadusky T. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO) Kidney International 2022 102 5 974 989 10.1016/j.kint.2022.08.012 36202661
150 Laurent S. Antihypertensive drugs Pharmacological Research 2017 124 116 125 10.1016/j.phrs.2017.07.026 2-s2.0-85027531119 28780421
151 Agarwal R. Kolkhof P. Bakris G. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes The New England Journal of Medicine 2020 383 23 2219 2229 33264825
152 Zhang Z. Zhang L. Xu H. Effect of astragalus polysaccharide in treatment of diabetes mellitus: a narrative review Journal of Traditional Chinese Medicine 2019 39 1 133 138 32186034
153 Guo M.-F. Dai Y.-J. Gao J.-R. Chen P.-J. Uncovering the mechanism of Astragalus membranaceus in the treatment of diabetic nephropathy based on network pharmacology Journal Diabetes Research 2020 2020 1, article 5947304 10.1155/2020/5947304
154 Alshehri A. S. Kaempferol attenuates diabetic nephropathy in streptozotocin-induced diabetic rats by a hypoglycaemic effect and concomitant activation of the Nrf-2/Ho-1/antioxidants axis Archives of Physiology and Biochemistry 2023 129 4 984 997 10.1080/13813455.2021.1890129 33625930
155 Luo W. Chen X. Ye L. Kaempferol attenuates streptozotocin-induced diabetic nephropathy by downregulating TRAF6 expression: the role of TRAF6 in diabetic nephropathy Journal of Ethnopharmacology 2021 268, article 113553 10.1016/j.jep.2020.113553 33152432
156 Sharma D. Kumar Tekade R. Kalia K. Kaempferol in ameliorating diabetes-induced fibrosis and renal damage: an in vitro and in vivo study in diabetic nephropathy mice model Phytomedicine 2020 76, article 153235 10.1016/j.phymed.2020.153235 32563017
157 Sharma D. Gondaliya P. Tiwari V. Kalia K. Kaempferol attenuates diabetic nephropathy by inhibiting RhoA/Rho-kinase mediated inflammatory signalling Biomedicine & Pharmacotherapy 2019 109 1610 1619 10.1016/j.biopha.2018.10.195 2-s2.0-85056602358 30551415
158 Lei D. Chengcheng L. Xuan Q. Quercetin inhibited mesangial cell proliferation of early diabetic nephropathy through the Hippo pathway Pharmacological Research 2019 146, article 104320 10.1016/j.phrs.2019.104320 2-s2.0-85067562135 31220559
159 Liu Y. Li Y. Xu L. Quercetin attenuates podocyte apoptosis of diabetic nephropathy through targeting EGFR signaling Frontiers in Pharmacology 2021 12, article 792777
160 Lu Q. Ji X.-J. Zhou Y.-X. Quercetin inhibits the mTORC1/p70S6K signaling-mediated renal tubular epithelial-mesenchymal transition and renal fibrosis in diabetic nephropathy Pharmacological Research 2015 99 237 247 10.1016/j.phrs.2015.06.006 2-s2.0-84937561370 26151815
161 Tong F. Liu S. Yan B. Li X. Ruan S. Yang S. Quercetin nanoparticle complex attenuated diabetic nephropathy via regulating the expression level of ICAM-1 on endothelium International Journal of Nanomedicine 2017 Volume 12 7799 7813 10.2147/IJN.S146978 2-s2.0-85032692803 29123394
162 Wan H. Wang Y. Pan Q. Quercetin attenuates the proliferation, inflammation, and oxidative stress of high glucose-induced human mesangial cells by regulating the miR-485-5p/YAP1 pathway International Journal of Immunopathology and Pharmacology 2022 36, article 20587384211066440
163 Feng X. Bu F. Huang L. Xu W. Wang W. Wu Q. Preclinical evidence of the effect of quercetin on diabetic nephropathy: a meta-analysis of animal studies European Journal of Pharmacology 2022 921 p. 174868 10.1016/j.ejphar.2022.174868 35248552
164 Huang Q. Chen H. Yin K. Formononetin attenuates renal tubular injury and mitochondrial damage in diabetic nephropathy partly via regulating Sirt1/PGC-1α pathway Frontiers in Pharmacology 2022 13, article 901234 10.3389/fphar.2022.901234 35645821
165 Lv J. Zhuang K. Jiang X. Huang H. Quan S. Renoprotective effect of formononetin by suppressing Smad3 expression in Db/Db mice Diabetes, Metabolic Syndrome and Obesity 2020 Volume 13 3313 3324 10.2147/DMSO.S272147
166 Oza M. J. Kulkarni Y. A. Formononetin attenuates kidney damage in type 2 diabetic rats Life Sciences 2019 219 109 121 10.1016/j.lfs.2019.01.013 2-s2.0-85059954406 30641085
167 Zhuang K. Jiang X. Liu R. Formononetin activates the Nrf2/ARE signaling pathway via Sirt1 to improve diabetic renal fibrosis Frontiers in Pharmacology 2020 11, article 616378
168 Kalai F. Z. Boulaaba M. Ferdousi F. Isoda H. Effects of isorhamnetin on diabetes and its associated complications: a review of in vitro and in vivo studies and a post hoc transcriptome analysis of involved molecular pathways International Journal of Molecular Sciences 2022 23 2 p. 704 10.3390/ijms23020704 35054888
169 Matboli M. Ibrahim D. Hasanin A. H. Epigenetic modulation of autophagy genes linked to diabetic nephropathy by administration of isorhamnetin in type 2 diabetes mellitus rats Epigenomics 2021 13 3 187 202 10.2217/epi-2020-0353 33406900
170 Kambale E. K. Quetin-Leclercq J. Memvanga P. B. Beloqui A. An overview of herbal-based antidiabetic drug delivery systems: focus on lipid- and inorganic-based nanoformulations Pharmaceutics 2022 14 10 p. 2135 10.3390/pharmaceutics14102135 36297570
171 Nie X. Chen Z. Pang L. Oral nano drug delivery systems for the treatment of type 2 diabetes mellitus: an available administration strategy for antidiabetic phytocompounds IJN 2020 Volume 15 10215 10240 10.2147/IJN.S285134 33364755
